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Chapter 1 
General Introduction 
In 1963 a massive increase in the number of dense particles within the 
cytoplasm of hepatocytes was described after treatment of rats wi th 
Clofibrate (Paget et al., 1963). Two years later the dense particles were 
identified as peroxisomes (Hess et al., 1965; Svoboda and Azarnoff, 
1966). In the following years it was shown that structurally not related 
xenobiotics could also produce this increase in the size and number of 
peroxisomes within liver cells. This effect is now known as peroxisome 
proliferation. Compounds classified as peroxisome proliferating agents have 
various commercial applications, including plasticizers such as di(2-ethyl-
hexyllphthalate (DEHP) and drugs as Clofibrate and ciprofibrate. 
Clofibrate was one of the first peroxisome proliferating compounds to be 
identified as a rat liver carcinogen (Reddy and Qureshi, 1979). In 1980 
Reddy et al. suggested that peroxisome proliferators represent a novel class 
of hepatocarcinogens. As these chemicals are neither ONA-reactive nor 
mutagenic, mechanisms inducing carcinogenicity are not very well under-
stood. In addition species differences in the sensitivity for peroxisome 
proliferation have been described. For these reasons it is hard to assess the 
hazard of these compounds to man. 
During the last years a number of excellent reviews have been published 
about peroxisome proliferating compounds (Reddy and Lalwai, 1983; 
Thomas and Thomas, 1985; Turnbull en Rodricks, 1985; Albro, 1986; 
Hawkins et al., 1987; Stott, 1988; Conway et al., 1989; Moody et al., 
1991 ; Moody et al., 1992). In this chapter a brief description of the current 
knowledge on the toxicity of peroxisome proliferating compounds is given. 
In the last paragraph an outline of our studies on the peroxisome prolifera-
ting compound DEHP is presented. 
1.1 - Inducers of peroxisome proliferation 
Peroxisome proliferating compounds can be identified by morphometry 
studies of liver tissue (figure 1 ) or by determining the activities of peroxiso-
mal ß-oxidation enzymes in liver homogenates after treatment of rats or 
mice wi th these compounds. The activity of peroxisomal palmitoyl-CoA 
oxidase is the most sensitive marker for peroxisomal changes (Tomaszew-
ski et al., 1987). 
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To date more than 60 xenobiotics including hypolipidaemic drugs, 
herbicides, leukotriene antagonists and plasticizers have been classified as 
peroxisome proliferating compounds (for review: Moody et al., 1991). The 
chemicals belonging to this group are structurally quite divers. Common to 
most of the compounds is that they either are, or can be converted to 
hydrophobic carboxylic acids by hydrolysis or by oxidation, and that these 
carboxylic acids can not be metabolized by mitochondrial ß-oxidation (Berge 
étal., 1992). 
In addition to xenobiotic chemicals, it has been observed that several 
nutritional and physiological states can induce peroxisome proliferation in 
the rat liver. These include high fat diets, vitamin E deficiency, alloxan 
diabetes, starvation and cold adaptation (for review: Hawkins et al., 1987). 
These factors may constitute a separate class of inducers since there 
appears to be a limit (i.e., circa twofold) to the increase in peroxisomal 
volume or peroxisomal enzyme activity caused by these factors, whereas 
induction by xenobiotics may be 30-fold or more (Moody et al., 1991). 
Not all the chemicals induce peroxisome proliferation to the same 
extend. Fenofibrate, ciprofibrate, Wy-14,643 and the perfluoro fatty acids 
are very potent inducers, whereas DEHP, DEHA and aspirin are much 
weaker (Barber et al., 1987; Sharma et al., 1988). Differences in absorpti-
on, metabolism, distribution and excretion kinetics may play a role in the 
varying potency of these chemicals to induce peroxisome proliferation in 
vivo. However, data obtained in vitro has also demonstrated significant 
differences in potency of these compounds (Gray et al., 1983; Lake et ai, 
1984). Conflicting results have been reported about sex differences in 
sensitivity for peroxisome proliferation (Watanabe et al., 1989; Kawashima 
et al., 1989; Sundseth and Waxman, 1992). 
Peroxisome proliferation is tissue specific. The most pronounced effects 
are determined in hepatocytes, with a limited response also occurring in 
renal cortex and intestinal mucosa (Nemali et al., 1988; Reubsaet et al., 
1990). Rat hepatocytes transplanted into the anterior chamber of the eye 
do still respond to peroxisome proliferating compounds (Rao er al., 1986), 
suggesting that hepatocytes possess liver-specific control mechanisms 
required for the induction of peroxisome proliferation. 
Induction of peroxisome proliferation may occur relatively rapid. Hepatic 
acyl-CoA oxidase mRNA was induced 13-fold and enzyme activities were 
2-fold increased 24 h after dosing (Bell et al., 1991a). The effects are 
rapidly reversible following the termination of dosing (review: Reddy and 
Lalwai, 1983; Stott et al., 1988). 
Many of the characteristics of peroxisome proliferation in the intact 
animal can readily be observed in rat hepatocytes, treated in vitro wi th 
peroxisome proliferating compounds (review: Bieri et al., 1990). 
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Figure 1 - Effect of feeding of DEHP on the number and volume of peroxisomes in 
the liver of rats. Peroxisomes are indicated by a P. Left: control liver, right: liver of 
DEHP treated rat (x ± 15,000). (photo by Jeanne Pertijs, Dept of Toxicology, 
University of Nijmegen). 
1.2- Peroxisomes 
A number of enzymes are found in peroxisomes (for reviews on the 
biochemistry of peroxisomes: Tolbert, 1981 ; de Duve, 1983; Borst, 1989, 
van den Bosch et al., 1992). Knowledge on the function of peroxisomes 
has expanded since a new group of genetic disorders have been described 
in which peroxisomal functions are impaired (for review: Schutgens et al., 
1986). 
An important function of peroxisomes is their role in lipid metabolism. 
The peroxisomal fatty acid ß-oxidation system is very similar to the ß-
oxidation system as present in mitochondria, however different enzymes 
are utilised. In mitochondria the first step in the ß-oxidation of fatty acids is 
catalysed by acyl-CoA dehydrogenases. The electrons are transferred to the 
respiratory chain and are used to produce adenosine triphosphate (ATP). 
Lacking an electron transport system, the first enzyme of the peroxiso-
mal ß-oxidation pathway, an acyl-CoA oxidase, transfers two electrons to 
molecular oxygen to form hydrogen peroxide. Hydrogen peroxide is degra-
ded by catalase which is also located in peroxisomes (Tolbert, 1 9 8 1 ; de 
Duve, 1983). 
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The function of the peroxisomal ß-oxidation system appears to be the 
shortening of fatty acids that are poorly oxidized by the mitochondria (e.g. 
long chain fatty acids) into fragments that can be oxidized by the mito-
chondria. In addition the peroxisomal ß-oxidation system has a high affinity 
for dicarboxylic acids and ω-hydroxy fatty acids, which are poorly metabo­
lized by the mitochondrial ß-oxidation system (Reubsaet et al., 1988; 
Vamecq and Draye, 1989; Poosch and Yamazaki, 1989; Suzuki et al., 
1989). 
1.3- Liver carcinogenesis 
Anatomically, the liver lies on the main route by which substances 
absorbed from the intestine pass into the systemic circulation. Bioche-
mically, it possesses an array of enzymes which are capable of metaboli-
zing most xenobiotics and endogenous compounds. Because of this the 
liver is most frequently affected in carcinogenicity studies (IARC, 1987). 
In two-stage models of liver carcinogenesis, chemicals may contribute 
to cancer risk by acting at the first stage (initiation) and/or the second 
stage (promotion) of tumour formation (review: Dragan and Pitot, 1992). 
Initiation is easily demonstrated for chemicals that are genotoxic and cause 
a modification of the DNA bases. Initiation involves the irreversible forma-
tion of individual cells possessing the potency to expand clonally under the 
influence of promoting agents. Promotion has been defined as an reversible 
enhancement of the proliferation and the genetic expression of initiated 
cells. 
Mechanisms of non-genotoxic carcinogens are much less understood. 
Barrett et al. (1987) mentioned some possible mechanisms, i.e. 1) unusual 
metabolic activation, 2) indirect mutagenesis, for example by interfering 
with spindle assembly during mitose leading to chromosomal abberations, 
by reducing the efficiency of DNA repair mechanisms or by altering the 
methylating state of DNA and 3) alternatively, some non-genotoxic carcin-
ogens might mimic the effect of natural signal transduction factors and 
therefore perturb normal cell growth and differentiation. Schulte-Hermann 
et al. (1983) suggested that non-genotoxic agents could enhance tumour 
growth in rodent bioassays by facilitating the development of tumours from 
cells that were spontaneously initiated. Cohen and Ellwein (1991) have 
suggested that non-genotoxic chemicals can initiate carcinogenesis if 
exposure leads to increased cell proliferation. This initiation may be attribu-
ted to a low risk of genetic alteration inherent with replicative DNA synthe-
sis. 
Numerous studies indicate that peroxisome proliferating compounds are 
non-genotoxic agents (for review: Turnbull and Rodricks, 1985; Stott, 
1988; IARC, 1987). Occasionally positive responses have been reported 
but this is always marked by reservations with the experimental protocol 
and lack of reproducibility in other laboratories. 
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The evidence of carcinogenicity of DEHP comes from a National 
Toxicology Program bioassay (NTP, 1982). In this study rats and mice 
were fed a diet containing DEHP for t w o years. The incidence of hepato­
cellular carcinomas was statistically significant in female rats and male and 
female mice. The International Agency for Research on Cancer (IARC, 
1987) has evaluated the carcinogenicity studies performed wi th peroxi­
some proliferators and has classified DEHP and nafenopin as a group 2b 
carcinogen ( = "agent is possibly carcinogenic to humans") and di(2-ethyl-
hexyDadipate (DEHA) and Clofibrate as a group 3 carcinogen ( = "agent is 
not classifiable as to its carcinogenicity to humans"). Also for other peroxi­
some proliferating compounds (positive) carcinogenicity studies have been 
reported, although these compounds have been tested wi th small numbers 
of animals (for review: Stott, 1988; Conway et af., 1989). The carcino­
genic potency of various peroxisome proliferating compounds differs 
considerable. For example rats fed a diet containing 0 . 1 % Wy-14,643 
produce a 1 0 0 % liver tumour incidence compared wi th none in rats fed a 
diet with 1.2% DEHP (Marsman et al., 1988). 
Tumorigenesis induced by genotoxic carcinogens follows a progression 
from altered foci , neoplastic nodules to hepatocellular carcinomas (Pitot, 
1990). In tumours induced by peroxisome proliferating compounds a similar 
progression is observed. Peroxisome proliferator-induced altered cells have 
like cells induced by other hepatocarcinogens, decreased ATPase and 
glucose-6-phosphatase activities and are resistant to iron accumulation 
during dietary overload. However, these cells do not have enhanced 
activities of /-glutamyl transpeptidase, glutathione S-transferase π, or σ-
fetoprotein (for review: Reddy and Rao, 1987). 
1.4 - Possible mechanisms in hepatocarcinogenesis by 
peroxisome proliferating compounds 
Two theories have been advanced to explain by which mechanisms 
peroxisome proliferating compounds induce carcinogenesis. One theory 
explains the carcinogenicity as a direct result of peroxisome proliferation 
and the other theory proposes that peroxisome proliferators have a promo-
tor activity (for review: Conway et al., 1989). 
1.4.1 - Peroxisome proliferating compounds and oxidative 
stress 
A correlation exists between the ability of compounds to induce 
proliferation of peroxisomes and their hepatocarcinogenicity upon chronic 
administration to rodents (Reddy and Lalwai, 1983; Barber et al., 1987). 
The oxidative stress hypothesis tries to link peroxisome proliferation with 
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DNA damage (review: Rao and Reddy, 1987). In this model, the enhanced 
production of hydrogen peroxide by the peroxisomal ß-oxidation system is 
larger than the ability of hydrogen peroxide degrading enzymes, and results 
in a slow accumulation of oxidative damage to the genome. Activities of 
enzymes like glutathione peroxidase, glutathione transferase and superoxide 
dismutase are decreased by peroxisome proliferating compounds, which 
might result in higher concentrations of hydrogen peroxide in the cytosol 
(Furukawa et al., 1985; Lake et al., 1987). However, hepatic capacities of 
hydrogen peroxide degrading enzymes may still exceed the hydrogen 
peroxide-generating levels (Tamura et al., 1990). 
A number of studies provides evidence for this theory. Treatment of 
rats wi th a peroxisome proliferating compound simultaneously with the 
antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole prevents the 
formation of tumours (Rao et al., 1984). The number of 8-hydroxydeoxy-
guanosine and 5-hydroxymethyl-2-deoxyuridine DNA adducts were 
increased after treatment of rats wi th peroxisome proliferating compounds 
(Kasai et al., 1989; Takagi et al., 1990 and 1991 ; Srinivisan and dauer t , 
1990). Unidentified DNA alterations were detectable by the 32P post-
labelling assay after chronic administration of ciprofibrate and Wy-14,643 
to rats (Randerath et al., 1991). 
DNA damage induced by activated oxygen might result in DNA breaks, 
which can be detected by alkaline elution of cellular DNA. Inconsistent 
results have been reported about these experiments after treatment of rats 
wi th peroxisome proliferating compounds (Bentley et al., 1987; Kornbrust 
et al., 1984; Tamura et al., 1991 ; Nilsson et al., 1991). Attempts to 
induce DNA repair or unscheduled DNA synthesis by peroxisome prolife-
rating agents, which might be expected if DNA-modifying active oxygen 
radicals were formed, have, so far, been unsuccessful (dauer t et al., 1984; 
Smith-Oliver and Butterworth, 1984; Cattley et al., 1988; Nilsson et al., 
1991). Numerous tumours were observed in rats fed Wy-14,643, but none 
in rats fed DEHP despite the fact that DEHP produced only 2 5 % less 
peroxisome proliferation than Wy-14,643 (Marsman et al., 1988). In old 
rats treated wi th nafenopin more tumours were observed than in young 
rats, although no differences in parameters associated with oxidative stress 
were found (Huberefe / . , 1991). 
Lipid peroxidation products like diene conjugate formation have been 
reported after long-term treatment of rats with peroxisome proliferating 
compounds and a correlation was found between conjugated diene formati-
on and carcinogenicity (Lake et al., 1987; Conway et al., 1989a; Goei er 
al., 1986; Cattley et al., 1987). The formation of the pigment lipofuscin 
might be a predictor for tumour formation by peroxisome proliferating 
compounds (Lake er al., 1987; Conway er al., 1989a; Marsman et al., 
1992). It has been proposed that lipofuscin is generated by the poly-
merization of oxidized lipid within the lysosome, and might be used as a 
marker for oxidative stress (Reddy et al., 1982). There appears to be a 
correlation between the potency of a peroxisome proliferating carcinogen 
and the level of accumulated hepatic lipofuscin (Cattley et al., 1987; 
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Conway et al., 1989a; Marsman et al., 1992). 
Summarizing: although there is some evidence that peroxisome prolife-
rator-induced hepatocarcinogenicity is associated with oxidative stress, 
definitive evidence that this is the primary mechanism responsible for 
tumour formation is lacking. 
1.4.2 - Peroxisome proliferating compounds act as 
promotors 
The rate of cell proliferation is considered to be important in non-geno-
toxic carcinogenesis since cell proliferation might lead to increased chances 
of fixation of DNA damage as well as an enhanced conversion rate of initia-
ted cells to tumour cells. Quantification of mitotic figures, autoradiographic 
quantification of labelled nuclei after pulse labelling with tritiated thymidine 
and scintillation counting of thymidine incorporation into liver DNA are 
methods to study cell proliferation (Ward et al., 1984; Smith-Oliver and 
Butterworth, 1987; Butterworth et al., 1984; Butterworth et al., 1987 and 
Marsman et al., 1988). These studies indicate that DEHP and other peroxi-
some proliferating compounds cause a rapid burst in cell proliferation during 
the first 7 days of treatment and then cell proliferation reverts to normal 
levels despite continued administration of the compound. Differences in 
potency to induce tumours are not reflected in differences in DNA synthe-
sis during the first 7 days of treatment with DEHP and Wy-14,643 (Mars-
man et al., 1988), so it has been argued that it is unlikely that this rapid 
burst in cell proliferation is related to the carcinogenicity of these com-
pounds (Conway et al., 1989). 
Chronic elevation of the hepatocyte replication rate have been related 
to the carcinogenicity of peroxisome proliferating compounds (Marsman et 
al., 1988). However, persistent replicative DNA synthesis has only been 
reported for Wy-14,643 but not for other potent carcinogenic, peroxisome 
proliferating compounds like Clofibrate, nafenopin and LY-171883 (Mars-
man et al., 1988; Eachoera/., 1991; Marsman étal., 1992). 
It has been suggested that sustained replication of subpopulations of 
hepatocytes are involved in the carcinogenic process. Two cell types, large 
cells, uniformly basophilic (Cattley et al., 1991; Marsman et al., 1992) and 
small cells, heterogeneously basophilic (Kraupp- Grasl et al., 1990 and 
1991) might be involved in this process. 
Recently, it has been reported that after treatment with Wy-14,643 
and with nafenopin more tumours were found in the livers of old rats when 
compared to young rats (Kraupp-Grasl et al., 1991, Cattley et al., 1991). 
Since old rats might have higher number of spontaneously initiated cells 
these experiments support the theory that peroxisome proliferating com-
pounds are promotors of carcinogenesis. 
The use of initiation-promotion protocols can provide more insight into 
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the carcinogenic action of peroxisome proliferating compounds (for review: 
Popp et al., 1987; Conway et al., 1989). Quantification of altered hepatic 
foci (AHF) is commonly used as an indicator of carcinogenicity (Pitot, 
1990). However, this method is less useful in studying peroxisome prolife-
rating compounds since the ratio of AHF and tumours is lower with peroxi-
some proliferating compounds than with genotoxic hepatocarcinogens 
(review: Conway et al., 1989). This may explain the variable results in 
initiating/promoting studies which only measured altered cell transfor-
mation. In studies in which tumour formation was used as an endpoint 
peroxisome proliferating compounds were identified as promoters (review: 
Conway et al., 1989). Initiating activity has not yet been identified. Studies 
in which initial treatment with DEHP in rats (Garvey et al., 1987; Williams 
et al., 1987) or mice (Ward et al., 1986) and ciprofibrate and Wy-14,643 
in rats (Cattley et al., 1989; dauert and Clark, 1989) were followed by 
various promotion regimes failed to reveal any initiating activities of these 
compounds. 
Summarizing: It is likely that peroxisome proliferating compounds have 
a promotor activity in carcinogenesis, however it has not been demonstra-
ted that chemically induced cell proliferation is the primary mechanism by 
which these compounds induce cancer (Melnick, 1992). Peroxisome prolife-
rators have liver tumour incidence rates approaching 100%, which have 
not been reported for other promoters (Moody et al., 1991). For this reason 
it is likely that other factors play a role in the carcinogenic process as well. 
1.5 - Cytochrome P450 
Cytochrome P450 is a family of haem based enzymes which perform a 
wide range of oxidative reactions (for review: Porter and Coon, 1991). The 
enzymes are membrane bound in the smooth endoplasmic reticulum or in a 
few cases, the mitochondrial inner membrane. A classification was devised 
by comparing amino acid sequences of individual cytochrome P450 enzy-
mes with each other. Of the 27 gene families so far described, 10 exist in 
all mammals (Nebert et al., 1990). Six of these are small families of one or 
two members involved in pathways of steroidogenesis in highly specialized 
tissues or in bile acid synthesis. Three families encode drug metabolizing 
enzymes, and one family (Cytochrome P450 4) consist of P450s that 
hydroxylate fatty acids (for review: Gibson, 1989). 
1.5.1 - Cytochrome P450 4A1 
A large increase in the terminal hydroxylation of fatty acids was 
reported in 1980 after administration of the peroxisome proliferators 
clobuzarit and methylclofenapate to rats (Parker and Orton, 1980). Subse-
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lauric acid 
(ω-U-hydroxylauric acid ω-hydroxylauric acid 
Figure 2 - Lauric acid is the marker substrate for the determination of cytochrome 
P450 4A1 activity. After incubation of microsomal liver fractions and lauric acid, 
in the presence of NADPH, ω-hydroxylauric acid and (ω-D-hydroxylauric acid are 
formed. Lauric acid ω-hydroxylation activity is most characteristic for cytochrome 
P450 4A1 enzymes. 
quently, an cytochrome P450 enzyme was purified to homogeneity from 
Clofibrate induced rat liver. This enzyme was termed cytochrome P-452, 
based on the wavelength absorption maximum of the ferrous-carbonmono-
xide adduct of the haemoprotein. The pure protein has a molecular weight 
of 5 1 . 5 0 0 Da and possesses an extremely high substrate specificity, the 
preferential substrate being lauric acid. Lauric acid is metabolized to ω-hy­
droxylauric acid, with trace amounts of the (w-D-hydroxylauric acid being 
formed (Tamburini et al., 1984) (figure 2). According to the classification of 
Nebert et al. (1990) cytochrome P452 is now named P450 4A1 (before 
1990: P450 IVA1). Cytochrome P450 4A1 has a highly structured active 
site that steric suppresses (ω-D-hydroxylation in order to deliver the 
oxygen to the thermodynamically disfavoured terminal carbon (CaJacob et 
al., 1988). The nucleotide sequences of the cDNAs coding for cytochromes 
P452 and P450LAw, an enzyme purified and characterized by Hardwick et 
al., 1987, have been shown to be virtually identical (Hardwick et al., 1987; 
Earnshaweí al., 1988). 
The precise number of genes in the P450 4 family are not known at 
present. At least 3 clofibrate-inducible cytochrome P450 4 gene products 
are found in liver and kidney of rats (Kimura et al., 1989a en b). Cyto-
chrome P450 4 enzymes are constitutively expressed in both liver and 
kidney. The enzymes are inducible in both tissues (Kimura et al., 1989a 
and b; Sharma et al., 1989). 
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1.6. Mechanisms in peroxisome proliferation 
Many studies were aimed at discovering the initial trigger for peroxiso-
me proliferation. A substrate overload-perturbation of lipid metabolism is 
mentioned in most theories <for review: Lock et al., 1989. Berge et al., 
1992). This substrate overload is either a result of lipolysis occurring 
outside the liver wi th a subsequent influx of fatty acids into the liver, or is 
a consequence of the peroxisome proliferating compounds or their metabo-
lites perturbing lipid metabolism within the liver, for example inhibition of 
mitochondrial fatty acid oxidation (Veitch et al., 1989, Foxworthy and 
Eacho, 1988). In this latter model the inducer directly inhibits mitochondrial 
ß-oxidation enzymes, and/or the carnitine acyltransferase responsible for 
transport of fatty acids across the mitochondrial membrane. 
A variant on the substrate overload theory postulates that peroxisome 
proliferation by xenobiotics and by different metabolic states is mediated by 
increased levels of long-chain acyl-CoA (Berge and Aarsland, 1985) Since 
many peroxisome proliferating compounds possess a carboxyhc acid group, 
or a group that can be oxidized to a carboxyhc group, several authors have 
dealt wi th the idea that formation of the CoA esters of peroxisome pro-
liferators is a prerequisite for peroxisome proliferating activity (Hertz et al., 
1985; Bronfman et al., 1986; Aarsland and Berge, 1 9 9 1 ; Berge étal., 
1992). 
1.6.1 - Peroxisome proliferation and cytochrome P450 4A1 
Studies with peroxisome prohferators in rats have demonstrated an 
excellent correlation between induction of microsomal P450 4A1 and lauric 
acid ω-hydroxylation on the one hand and peroxisomal volume and peroxi­
somal palmitoyl-CoA oxidation on the other (Lake et al., 1984 and Sharma 
et al., 1988). Sharma er al. (1988) have hypothesized that cytochrome 
P450 4A1 induction is mechanistically interrelated to peroxisome proliferati­
on (figure 3). According to this model induction of cytochrome P450 4 A 1 
gives an increase in cellular ω-hydroxy fatty acids that are subsequently 
oxidized to dicarboxyhc acids. These dicarboxyhc acids are good substrates 
for the peroxisomal ß-oxidation system, but not for the mitochondrial ß-
oxidation system (see paragraph: 1.2). According to this model peroxisome 
proliferation is a response of peroxisomes to a substrate overload of one of 
its preferred substrates, in which P450 4A1 is a necessary requisite. After 
treatment wi th peroxisome proliferating compounds P450 4A1 RNA is 
detected earlier than acyl-CoA oxidase RNA (Bien et al., 1990; Milton et 
al., 1990; Bell et al., 1991 a and b). Inactivation of cytochrome P450 4A1 
by 1-aminobenzotriazole inhibits peroxisome proliferation (Ortiz de Mantel-
lano et al., 1992). The induction of cytochrome P450 4A1 therefore 
appears to be an early and key event in peroxisome proliferation. 
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uptake of peroxisome proliferating compound 
in hepatocytes. 
I 
induction of cytochrome P450 4 enzymes 
I 
increased ω-hydroxylation of fatty acids 
I 
increased formation of (long-chain) dicarboxylic acids 
I 
increased peroxisomal B-oxidation 
I 
chain-shortened fatty acids 
I 
mitochondrial B-oxidation 
Figure 3 - Scheme to show the proposed inter-relationship of microsomal and 
peroxisomal changes in fatty acid metabolism after treatment of rats with peroxi­
some proliferating compounds, according to the model of Sharma et al., 1988. 
1.6.2 - Peroxisome proliferation is receptor mediated 
Which control mechanisms are influenced to result in a proliferation of 
hepatic peroxisomes is unknown at present. The idea of a receptor media­
ted activation of specific genes is supported by the tissue-specific nature of 
proliferation, the uniform enzymatic responses, the rate of the increase in 
transcriptional activation, and induction of peroxisome proliferation in 
cultured or transplanted hepatocytes (Moody et al., 1991). 
A member of the nuclear hormone receptor family termed PPAR (Pe­
roxisome Proliferator Activated Receptor) was activated by the addition of 
several peroxisome proliferators (Isseman and Green, 1990). Nuclear 
hormone receptors are intracellular proteins that bind their ligand wi th high 
affinity and specificity and in addition recognize short DNA motifs. Binding 
of the ligand-receptor complex to DNA can either activate or repress 
specific gene expression (for review: Green, 1992). A good correlation was 
observed between the ability of peroxisome proliferating compounds to 
activate PPAR and their potency as either peroxisome proliferators or rat 
liver carcinogens. The tissue specific expression of PPAR compares well 
with the tissue specific induction of acyl-CoA oxidase by peroxisome 
proliferators (Isseman and Green, 1990). Recently, it was demonstrated 
that PPAR is a peroxisome proliferator activated transcription factor for the 
acyl-CoA oxidase gene (Tugwood et al., 1992). 
Recently, the cloning from the rat of a gene homologous to that enco­
ding mouse PPAR have been described (Göttlicher et al., 1992). This 
receptor was activated by arachidonic acid, linoleic acid and saturated fatty 
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1.7 - Species differences in the effects of peroxisome 
proliferating compounds 
Peroxisome proliferation has been demonstrated in most mammalian 
species that have been tested, however the dose required to produce 
recognizable proliferation varies widely among species (review: Rodricks 
and Turnbull, 1987; Stott et al., 1988). The mouse and rat are most 
responsive; the hamster has an intermediate response; and the guinea pig, 
marmoset, and other non-human primates are weakly responsive (Orton et 
al., 1984; Lake et al., 1984; Watanabe étal.. 1989; Lake et al., 1989). 
A morphological analysis of liver biopsy tissue from hyperlipidaemic 
patients receiving therapeutic dose level of Clofibrate (20-40 mg/kg.day), 
revealed a 1.5 fold increase in the number, and a 2 3 % increase in the 
volume density of hepatocellular peroxisomes (Hanefeld et al., 1983). In 
patients treated with gemfibrozol and fenofibrate no increase in hepato-
cellular peroxisomes was found (de la Iglesia et al., 1981 ; Gariot et al., 
1987; Blane and Pinaroli, 1980; Bliimcke et al., 1983). Measurements of 
peroxisomal enzymes have not been reported. An epidemiological study did 
not show an increase in cancer rate after the use of certain hypolipidemic 
drugs (Muldoon et al., 1990). Several in vitro studies suggest that human 
and non-human primate hepatocytes are relatively unresponsive to hypolipi-
demic drugs and phthalate ester plasticizers (Butterworth et al., 1989; 
Blaauboer et al., 1990; Foxworthy er al., 1990). Mechanisms behind these 
species differences in sensitivity for peroxisome proliferation are not very 
well understood (see chapter 6). 
Studies on species differences in the stimulation of liver cell replication 
have been very limited (Bieri et al., 1988; Styles et al., 1988). Stimulation 
of DNA synthesis has been observed in non-human primate hepatocytes at 
concentrations that do not cause peroxisome proliferation (Bieri et al., 
1988). 
1.8 - Outline of the studies described in this thesis 
In a panel discussion held in 1988 between scientists and regulatory 
policy experts no consensus could be achieved regarding several critical 
issues on the effects of DEHP on human health (Schulz, 1989). 
In figure 4 a scheme is presented which might be used in assessing the 
health effects of peroxisome proliferating compounds on humans. If 
peroxisome proliferation is indeed an important step in the development of 
cancer it is necessary to determine if man/primate are also sensitive for this 
effect. Since peroxisome proliferating agents are non-genotoxic 
carcinogens, extrapolation of the effects as found in rat/mouse to man 
might be based on the determination of a no-effect level. When this no-
effect level is known, it is possible to calculate a dose wi th no increased 
risk on the development of maliqnancv. When in addition information is 
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IS PEROXISOME PROLIFERATION AN INTERMEDIATE 
STEP TO CANCER ? 
NO 
The lack of responsiveness 
of human/primate 
hepatocytes to peroxisome 
proliferators can not be 
used to determine the 
toxicity to man 
YES 
YES 
Do human/primate 
hepatocytes respond in 
the same way as 
rat/mice hepatocytes ? 
YES, but 
Response is so small 
that these compounds 
are not very toxic 
to man 
Then man 
is equally susceptible 
to the toxicity 
of these compounds 
\ У 
Determine no-effect levels 
\ 
Determine exposure to peroxisome proliferating compounds 
• 
RISK-ASSESSMENT 
NO 
These 
compounds are 
not toxic for 
man. 
Figure 4 - Scheme t o assess the health effects of peroxisome proliferating 
compounds for humans The topics w e have studied are indicated in italic letters 
available on the exposure to peroxisome proliferating compounds, the risk 
of human exposure to these agents might be assessed. 
Our studies have been mainly focussed on one peroxisome proliferating 
agent, i.e. the Polyvinylchloride plasticizer di(2-ethylhexyl)phthalate. We 
have chosen this compound since environmental and occupational exposure 
to DEHP is wide (Gold et al., 1987). According to the scheme outlined in 
figure 4 our studies covered mainly two topics, i.e. the problem of species 
differences in peroxisome proliferation caused by DEHP and the develop­
ment of methods to determine exposure to DEHP. 
2. 
Our studies were designed to find answers on the following questions: 
What is the mechanism of action of peroxisome proliferating com­
pounds and how can species differences in sensitivity for peroxisome 
proliferation be explained? 
Are there specific biomarkers to assess exposure to peroxisome prolife­
rating compounds7 
What is the environmental and occupational exposure to DEHP? 
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Abstract 
In order to identify non-invasive, biochemical indicators of di(2-ethyl-
hexyDphthalate (DEHP) exposure, we have compared the effects in blood 
serum with biochemical effects in liver in rats fed a diet containing 0, 0.25, 
0.75 and 2 % DEHP for 2 weeks. After 3 days of treatment serum aryles-
terase activity levels and serum triglycerides were decreased to 60% and 
20% of control values, respectively. After a 2-week treatment with DEHP 
the effects were generally stronger. Compared to a control group, serum 
arylesterase activity levels, serum triglycerides and serum cholesterol were 
decreased to 40%, 20% and 50%, respectively. Serum Cholinesterase 
activity levels and serum albumin concentrations were increased by the 
DEHP treatment to 290% and 135% of control values, respectively. 
In the livers a hepatomegaly, an induction of cytochrome P-450 IVA1, 
and induction of the activity of palmitoyl-CoA oxidase and carnitine ace-
tyl-CoA transferase was found to be 180%, 1080%, 1300% and 1700% 
of control values, respectively. The liver is a more sensitive target for DEHP 
exposure compared to the biochemical effects in serum, but determination 
of the serum parameters can be used to determine early biological effects 
of exposure to DEHP. 
Introduction 
The phthalate ester di(2-ethylhexyl)phthalate (DEHP) is widely used as a 
plasticizing agent in numerous consumer plastic products and medical 
devices. DEHP belongs to the class of agents described as non-genotoxic, 
hypolipidaemic hepatocarcinogens. These chemicals have in common the 
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ability to induce peroxisome proliferation in the liver. It has been suggested 
that the hepatocarcinogenicity of DEHP and other peroxisome proliferating 
compounds is linked to peroxisome proliferation [1]. Peroxisome proli-
ferating agents induce a number of non-peroxisomal biochemical alterati-
ons [2]. The peroxisome proliferator Clofibrate has been reported to affect 
tissue carboxyesterase in liver, kidney and testis in rats and mice [3]. 
Dietary exposure of rats and mice to the peroxisome proliferating com-
pounds nafenopin and Clofibrate decreased serum arylesterase activity 
levels and increased serum Cholinesterase activity levels [4]. Both enzymes 
are carboxylic ester hydrolases and are involved in the detoxification of 
organophosphates. Peroxisome proliferation in the liver is associated with 
the induction of the activity of acyl-CoA oxidase, and carnitine acetyl-CoA 
transferase [2]. Recently, it was reported that treatment of rats with DEHP 
results in an induction of cytochrome P-450 IVA1 [5]. 
In order to identify sensitive, non-invasive biochemical indicators of 
exposure to DEHP we have investigated in this study the effect of DEHP on 
several biochemical parameters in serum (arylesterase activity levels, 
Cholinesterase activity levels, triglycerides, cholesterol, albumin) and 
compared with effects found in liver (mass, cytochrome P450 IVA1 
concentration and activities of acyl-CoA oxidase and carnitine acetyl-CoA 
transferase). 
Materials and Methods 
Chemicals 
DEHP (99.5% pure) was obtained from Janssen Chimica (Beerse, Belgi-
um). Leuko-2,7-dichlorofluorescin diacetate was a product of Eastman 
Kodak (Rochester N.Y., U.S.A.). Palmitoyl-CoA, acetyl-CoA, peroxidase, 
rat serum albumin (fraction V) were obtained from Sigma Chemical Co. (St. 
Louis, MO, U.S.A.) 
Antibodies against cytochrome P-450 IVA1 were a generous gift of Dr. 
G.G. Gibson (University of Surrey, U.K.). Triglycerides and cholesterol 
testkits were from Boehringer Mannheim (FRG). All other chemicals were 
obtained from commercial sources and were of the highest purity ob-
tainable. 
Animals and treatment. 
Male random-bred Wistar rats (173 ± 8 g body weight) were individual-
ly housed and fed ad libitum a pelleted diet, containing 22% protein, 4.8% 
fat and 67% carbohydrate. After 7 days of acclimatization four experimen-
tal groups were formed. These groups received a diet containing 0%, 
0.25%, 0.75% or 2% DEHP (w/w) for 14 days. This diet was custom 
synthesized RMH-TH by Hope Farms, Woerden, The Netherlands. The 
actual concentrations of DEHP in the food were determined by means of 
GC analysis. During the experiment food intake and body weight were 
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Table 1 - Food consumption during the administration of DEHP (g/day per kg 
body wt) and the calculated DEHP dose (g DEHP/day per kg body wt). 
% DEHP Before 0-3 days 0-14 days 
in diet experiment 
0% 
0.25% 
0.75% 
2.0% 
Food 
consumption 
90.3 ± 5.6 
88.1 ± 8.0 
88.8 ± 4.4 
89.7 ± 4.9 
Food 
consumption 
91.9 ± 6.9 
94.9 ± 6.9 
90.9 ± 0.68 
68.0 ± 7.0* 
DEHP 
dose 
0 
0.24 
0.68 
1.36 
Food 
Consumption 
72.2 ± 5.2 
71.4 ± 3.8 
71.4 ± 3.8 
68.6 ± 3.1 
DEHP 
dose 
0 
0.18 
0.52 
1.37 
All values are means ± SD of 4 rats. 
Statistically significant effects are indicated by * P<0.005. 
monitored daily. One day before the DEHP-treatment started and 3 and 14 
days after the start of the treatment blood was collected by orbitae punctu-
re. 
Animals were killed by decapitation and livers were perfused with 0 .9% 
NaCI (w/w) for 10 min. Livers were removed and immediately cooled in 
ice-cold buffer, consisting of 0.25M sucrose/2mM EDTA/10mM Tris-HCI 
(pH 7.4). Whole liver homogenates (20% w/v) were prepared in the same 
buffer by manual homogenization. Samples of whole liver homogenates 
were taken for the determination of peroxisomal and microsomal marker 
enzymes, the latter fraction prepared by a standard centrifugation method 
as described [6]. 
Biochemical assays 
Serum arylesterase (E.C. 3.1.1.2) activity was assayed according to the 
method of Kitchen [7] with phenylacetate as a substrate and in the presen-
ce of eserine sulfate, to inhibit Cholinesterase. Serum Cholinesterase (E.C. 
3.1.1.5) activity was measured as described by Butler et al. [8] using 
butyrylthiocholine as a substrate. Cholesterol was determined by the 
enzymatic method of Siedel [9] and triglycerides by the enzymatic method 
of Wahlefeld [10]. 
Acyl-CoA oxidase (with palmitoyl-CoA as a substrate) and carnitine 
acetyl-CoA transferase were measured in homogenates that were free-
ze-thawed 3 times. The acyl-CoA oxidase assay was based on the determi-
nation of hydrogen peroxide-dependent oxidation of leuko-difluorescin as 
described [11]. Carnitine acetyl-CoA transferase activity was measured at 
25 °C [12]. Cytochrome P-450 was determined by measurement of the CO 
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Figure 1 - Effect of consumption of a DEHP-containing diet for 3 (A) and for 14 
days (B) on serum arylesterase activity and serum Cholinesterase activity levels. 
Mean ± SD of 4 rats is presented. 
Statistically significant effects are indicated by * Ρ < 0.05, · · Ρ < 0.005 and 
· · · Ρ < 0.001. 
difference spectrum as described by Omura and Sato [13] . Cytochrome 
P-450 IVA1 was determined immunochemically with an ELISA method [ 5 ] . 
All assays were performed using saturating substrate concentrations and 
conditions of linearity with time and enzyme concentration. 
Other procedures. 
Serum albumin was measured according to Rodkey wi th crystalline rat 
serum albumin as standard [14]. Protein concentrations were determined by 
the method of Lowry er al. [15] with crystalline bovine serum albumin as a 
standard. Differences of the parameters after DEHP treatment compared to 
control values were tested for statistical significance using the t-test. A 
level of significance of ρ < 0 . 0 5 (two tailed) was chosen. 
Effects of DEHP on liver and serum 33 
Results 
The rats accepted the DEHP containing diet readily. Food consumption of 
rats receiving DEHP-containing diets was not statistically significantly 
different from the food consumption of rats using the control diet, except 
for the 2 % DEHP-diet group during the first 3 days. Based on the food 
intake a DEHP-dose could be calculated (table 1). The dose levels used in 
this study are lower than in most other published studies [16, 17]. 
Control serum samples of all 16 rats were collected before starting the 
experiment. The control values of serum arylesterase- and Cholinesterase 
activity and triglyceride-, cholesterol- and albumin concentrations were 
114 ± 15/ /mol /min.ml , 102 ± 13 nmol/min.ml, 2.4 ± 0.45 //mol/ml, 1.9 
± 0.3 ^mol/ml and 35.2 ± 3.7 mg/ml, respectively. 
The effect of DEHP administration for 3 and 14 days on serum aryles-
terase- and Cholinesterase activity levels, triglyceride-, cholesterol- and 
albumin concentrations are shown in figures 1 and 2, respectively. After 
DEHP treatment for a period of 3 days arylesterase activity levels were 
decreased to 6 0 % of control values and the triglyceride concentrations 
were decreased to 2 0 % of control values. Serum Cholinesterase activity 
levels and serum albumin concentrations were increased whereas no effect 
on serum cholesterol concentrations was found, except for the 2 % dose 
group. 
After DEHP treatment for a period of 14 days the effects were generally 
stronger. Compared to control values serum arylesterase activity levels 
(40%), triglyceride concentrations (20%) and cholesterol concentrations 
(50%) were decreased. On the contrary serum Cholinesterase activity 
levels (290%) and albumin concentrations were increased (135%). 
The monitoring of consumption of food shows that the decreased serum 
triglycerides- and cholesterol concentrations were an effect of the DEHP 
treatment and not from an altered intake of food (table 1). 
The effects of DEHP administration on liver parameters are shown in 
table 2. A dose-related hepatomegaly was found. In liver homogenates, a 
large increase in hydrogen peroxide production with palmitoyl-CoA as sub-
strate was found, typical for increase in acyl-CoA oxidase activity by the 
peroxisomal ß-oxidation pathway. Also carnitine acetyl-CoA transferase 
activities were highly enhanced. Proliferation of the hepatic endoplasmic 
reticulum results in the induction of cytochrome P-450 I V A I . Our data 
demonstrate that the initial cytochrome P-450 IVA1 concentration was 
shown to be 1.5% of total cytochrome P-450. Treatment with DEHP 
produced a 6-8 fold increase over constitutive levels in the dose groups 
studied. 
It appeared that the effects on the liver were much stronger compared to 
the effects in serum. 
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Figure 2 - Effect of consumption of a DEHP-containing diet for 3 (A) and for 14 
days (B) on serum triglyceride concentrations, serum cholesterol concentrations 
and serum albumin concentrations. Mean ± SD of 4 rats is presented. Statistically 
significant effects are indicated by * Ρ < 0.05, · · Ρ < 0.005 and *** Ρ < 
0.001. 
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Discussion 
The findings reported here demonstrate that rats fed a diet with DEHP 
develop an increased level of serum Cholinesterase activity and a decreased 
level of serum arylesterase activity. The serum arylesterase- and the serum 
Cholinesterase activity level are 40% and 292% of control values, respecti­
vely. Similar effects were found by Butler et al. [4] after treatment of rats 
and mice with Clofibrate and nafenopin. Rats fed a diet with 0.5% Clofibra­
te for 3 weeks showed increased serum Cholinesterase activity (194 to 
248% as compared to controls) and decreased serum arylesterase activity 
(27 to 39% as compared to controls). 
Since arylesterase activity is associated with the concentration of high-
density lipoprotein [7], Butler et al. [4] proposed that the decrease in serum 
arylesterase activity level found in rodents after treatment with nafenopin 
and Clofibrate is an effect of the lowered serum lipid levels. Our data 
demonstrate that both serum arylesterase activity level and serum trigly­
cerides are already altered after 3 days of DEHP treatment. 
Butler et al. [4] suggested that the elevated serum Cholinesterase activity 
level found after treatment of rodents with nafenopin and Clofibrate is a 
result of an increased liver mass, since Cholinesterase is synthesized in the 
liver by parenchymal cells and released promptly after synthesis [4]. Our 
data show that after treatment with DEHP Cholinesterase activity is increa­
sed to 290% of control values, but also the albumin is increased to 135% 
of control values. It is likely that the increase in serum Cholinesterase 
activity and the increase in serum albumin levels are both a result of an 
increased protein formation capacity of the liver caused by liver enlarge­
ment. The hypolipidaemic effects of DEHP were first described by Reddy 
er al. [16] and were confirmed in other studies. Our data demonstrate that 
the hypolipidaemic effects appear rapidly after exposure and at low dose 
levels. 
The administration of DEHP resulted in a pronounced hepatomegaly. The 
activities of the hepatic peroxisomal enzymes palmitoyl-CoA oxidase and 
carnitine acetyl-CoA transferase are increased by DEHP treatment. Tomas-
zewski er al. [18] have shown that acyl-CoA oxidase activity is the most 
suitable marker for peroxisomal changes caused by DEHP [17]. It has been 
reported [5, 6] that the increase in the number and size of peroxisomes in 
rats treated with peroxisome proliferators correlates well with the increased 
carnitine acetyl-CoA transferase activity, although it is not a specific 
peroxisomal enzyme. Increases in the activity of both enzymes are general­
ly accepted as indicators for peroxisome proliferation in the liver. Recently, 
it was shown that treatment of rats with peroxisome proliferating agents 
induces a specific cytochrome P-450 isoenzyme named cytochrome P-450 
IVA1 [5]. This induction shows a very strong correlation with an increased 
ω-hydroxylation activity of lauric acid. In our study we have also found a 
strong induction of this cytochrome P-450 IVA1 isoenzyme. 
The effect of DEHP on liver parameters is stronger compared to the 
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effect on biochemical parameters in serum. 
Whether peroxisome proliferating agents are able to affect serum 
esterase activity levels in humans is not yet known. If indeed the decrease 
of serum arylesterase activity is caused by the hypolipidaemic activity of 
DEHP, then this effect can be found in humans, since other compounds of 
the group of non-genotoxic peroxisome proliferating agents, like Clofibrate 
and nafenopin, are well known hypolipidaemic drugs used in human 
therapy. 
Although the liver is a more sensitive target for DEHP, blood serum 
indicators can be used to detect early biological changes as a result of 
DEHP exposure. 
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Abstract
The form ation o f w-hydroxy lauric acid from lauric acid is an indicator o f the 
activ ity  o f cytochrom e P450 IV family proteins. The tw o  main metabolites o f 
lauric acid, (w-1(- and w-hydroxylauric acid, have been completely separated 
by reversed-phase high-performance liquid chromatography. Measurement o f 
lauric acid hydroxylase activ itity  in microsomal liver samples, based on deriva- 
tization o f the substrate and metabolites w ith  the fluorescent agent 4-bromo- 
-m ethyl-6,7-di- methoxycoumarin, is a precise method (coëfficiënt o f variation 
= 7 .6%  and 10% , ui- and (w-1 (-metabolites, respectively) w ith  good sensiti- 
v ity  (signal-to-noise ratio in microsomal samples o f untreated rats >  20). In 
microsomal fractions from livers o f rats treated w ith  di(2-ethylhexyl)phthalate 
the extent o f the w-hydroxylation o f lauric acid increased dose-dependently 
(ca. ten fold). The (w-1 (-hydroxylase activ ity was not altered. A strong 
correlation between immunochemically determined cytochrom e P-450 IVA1 
and lauric acid w-hydroxylase activ ity was found (r = 0 .94, n = 30).
Introduction
The form ation o f w-hydroxylauric acid ( = 12-hydroxylauric acid) from  lauric 
acid is w idely acknowledged to be a marker o f the activ ity  o f the cytochrome 
P-450 IVA1 isoenzyme [1]. A fter treatment w ith  hypolipidaemic, peroxisome 
proliferating compounds such as clofibrate, nafenopin and di(2-ethyl- 
hexyDphthalate (DEHP), w-hydroxylase activ ity is induced in liver as well as in 
kidney [2, 3].
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Since the group o f hypolipidaemic, peroxisome proliferating compounds is 
classified as a unique class o f epigenetic hepatocarcinogens [4], much attenti- 
on has been paid to  these responses. Recently, Sharma et al. [2] postulated 
tha t a perturbation o f lipid metabolism in the liver results in a proliferation of 
peroxisomes. Disturbances in lipid metabolism are due to  an enhanced 
w-hydroxylation o f fa tty  acid by cytochrome P-450 IVA1.
The formation o f (w-) and (w-1 )-hydroxylauric acid (11-hydroxylauric acid) 
is usually determined by gas chromatography (GC) [5] or high performance 
liquid chromatography (HPLC) [6]. Since lauric acid and its metabolites have 
no UV absorption or fluorescence characteristics, detection in the HPLC 
method is usually achieved by radiochemistry which necessitates the use of 
radiolabelled lauric acid substrate. Recently, tw o  reports were published in 
which non-radioactive lauric acid was used as substrate. In one study, lauric 
acid and its metabolites were converted to a UV-absorbing ester derivative 
before the HPLC separation. However, co-eluting UV-absorbing peaks in 
organic solvent extracts o f microsomes were reported [7], Imaoka e t al. [8] 
determined lauric acid and its metabolites by HPLC w ith  fluorim etric detec­
tion, fo llow ing derivatization w ith 9-antryldiazomethane. However, no data on 
the sensitiv ity and reproducibility of this method were presented.
The aim o f the present study was to develop a reproducible and sensitive 
method for the determination of the hydroxylase activities towards lauric acid 
in microsomal preparations w ithout the necessity for radiolabelled substrates. 
Since 4-bromomethyl-6,7-dimethoxycoumarin (Br-mdmc) can be used as a 
fluorim etric derivatization agent for carboxylic acid [9], we applied this com- 
pound in the determination o f the (w)- and (w-1 )-hydroxy metabolites of lauric 
acid in microsomal fractions.
Experimental
Reagents and chemicals
Lauric acid, w-hydroxylauric acid and NADPH were obtained from  Sigma 
(St. Louis, MO, USA), (w-1 )-Hydroxylauric acid was a generous g ift o f Dr. S. 
Imaoka (Osaka City University Medical school, Osaka, Japan). 18-Crown-6 
ether and 4-(bromo-methyl)-6,7-dimethoxycoumarin were obtained from 
Aldrich (Milwaukee, W l, USA). DEHP was obtained from Janssen Chimica 
(Beerse, Belgium). Antibodies against cytochrome P-450 IVA1 were a gene­
rous g ift o f Dr. G. Gordon Gibson, University o f Surrey, U.K. All other chemi­
cals were o f the highest purity obtainable.
Chromatography
The analyses were performed using the HPLC gradiënt system model 8800 
from  Spectra Physics. A 20 //I portion was injected on to a 150 x 4 .6  mm i.d. 
Nucleosil C18 (5.0 //m) column (Machery-Nagel, Düren, Germany) (column 
temperature, 30°C , flow-rate, 1.0 ml/min). The solvent programme started 
isocratically w ith  67%  (v/v) methanol and 33%  water for 25 min, fo llowed by
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a 10-min linear gradiënt to  97%  (v/v) methanol and 3%  w ater in 10 min, and 
a hold fo r 5 min. The chromatograph was equipped w ith  a fluorescence 
spectrofotom eter (Shimadzu RF-530), interfaced w ith  an Apple II computer. 
The excitation wavelength was 340 nm, emission wavelength 420  nm. Peak 
areas were calculated using a Chromatochart program (Interactive Microwa- 
re).
The rate o f the hydroxylase reaction was calculated from  the fractional 
conversion o f lauric acid into (w-1)- and w-hydroxylauric metabolites. Con- 
centrations o f the hydroxylated metabolites formed were determined from 
their relative peak areas o f the total area o f the parent compound and metab­
olites. Since the methanol percentage increases during the run and methanol 
increases the fluorescence intensity o f the Br-mdmc derivatizing agent [9], 
peak areas o f [iv -1)- and w-hydroxylauric acid were corrected for reduced 
fluorescence.
Animals and treatment
Male random-bred Wistar rats (150 to 200 g) were pretreated by gastric 
intubation once a day w ith  DEHP for 3 consecutive days at the fo llow ing dose 
levels: 50, 100, 250, 500 and 1000 mg/kg body weight per day. Five or six 
animals were used in each group. Olive oil was used as a vehicle fo r DEHP 
adm inistration. Control animals were given olive oil at 5 m l/kg body weight 
per day. Animals were killed by decapitation 24h after the last dose. Livers 
were perfused w ith  0 .9%  NaCI (w /w) for 10 min. Whole liver homogenates 
(20%  w /v) were prepared in 0.25M  sucrose-2 mM EDTA and 10 mM Tris/HCI 
(pH 7.4). Microsomal fractions were prepared by a Standard centrifugation 
method [10].
Assay of u -  and («;-1)-hydroxylase activities towards lauric acid
The activities o f the microsomal fraction (1 mg protein) towards lauric acid 
was measured in a reaction mixture containing 200 nmol lauric acid in 2 ml of 
50 mM Tris-HCI (pH 7.5). The test-tubes were incubated for 5 min at 37 °C 
prior to  the addition o f 50 p\ of 40 mM NADPH to initiate the reaction. A fter 
10 min the reaction was stopped by the addition o f 300 //I o f 3M HCI. The 
reaction m ixture was extracted tw ice w ith  5 ml diethylether. The extracts 
were evaporated to  dryness under a gentle flow  o f nitrogen at 35 °C.
A 1-ml volume o f a solution o f 18-crown-6-ether in acetone (250 jt/g/ml) 
was added to  the dried extract. A fter the addition o f 1 mg dried potassium 
carbonate and 0.5 ml o f acetone w ith  Br-mdmc (2 mg/ml), the derivatization 
was performed at 70 °C for 45 min in a sealed test tube. The m ixture was 
evaporated to  dryness under a gentle flow  o f nitrogen at 40°C . The residue 
was dissolved in a fixed volume o f methanol, and an aliquot was analysed by 
HPLC.
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Figure 1 - Chromatograms of diethyl ether extracts of microsomal fractions of rat 
liver after derivatization with 4-bromomethyl-6,7-dimethoxycoumarin (Br-mdmc). 
Peaks: a/-1 = (a/-1)-hydroxylauric acid; w = w-hydroxylauric acid; LA - Lauric acid. 
Gradiënt elution as described in Experimental. (A) Chromatogram of authentic uj- and 
(w-D-hydroxylauric acid standards. (B) Chromatogram of lauric acid metabolites 
generated by a microsomal fraction of a DEHP-treated rat (1000 mg/kg body weight), 
after a 10-min incubation of 1 mg protein at 37 °C with NADPH. (C) as B, but 
without NADPH in the incubation mix.
Other methods
Cytochrome P-450 was determined from the CO-difference spectrum [11]. 
Cytochrome P-450 IVA1 was determined immunochemically by an enzyme- 
linked immunosorbent assay (ELISA) method described by Sharma et al. [2]. 
Protein concentrations were determined by the method o f Bradford [12].
Results and discussion
Figure 1 shows typical chromatograms obtained from authentic compounds 
(Figure 1A), and lauric acid metabolites generated by a microsomal fraction of 
the liver w ith  (Figure 1B) and w ithout NADPH (figure 1C), after derivatization 
w ith  a fluorescent compound. The retention times o f the esters o f (w-1)-hy- 
droxylauric acid, w-hydroxylauric and lauric acid were 19.5, 22 .0  and 40.0 
min, respectively. The (a/-1)- and a/-hydroxylauric acid formed in the presence 
o f NADPH by a microsomal fraction of the liver are clearly base-line separated
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Figure 2 - Effect of DEHP on (w-1)- and w-hydroxylase activity towards lauric acid in 
rat liver microsomes. Mean ±  S.D. values are presented. Each group consisted of 
five or six rats.
and are not detected in the absence o f NADPH. Interferences from fa tty  acids 
extracted from  the microsomal fractions were not observed.
The üj- and (w-1 )-hydroxylase activities towards lauric acid in microsomal 
fractions isolated from the livers o f rats treated w ith  DEHP (doses: 0, 50, 
100, 250, 500 and 1000 mg/kg body weight per day) are shown in Fig 2. A 
dose-dependent increase in the w-hydroxylase activ ity was observed, but no 
alteration in the (w-D-hydroxylase activ ity was found. Similar results have 
been reported by Sharma et al. [13].
The form ation o f w-hydroxylauric acid from lauric acid is accepted as a 
marker o f the activ ity  o f cytochrome P-450 IVA1 [1]. The cytochrome P-450 
IVA1 concentrations in the microsomal fractions have been determined w ith  
ELISA. The immunochemically determined cytochrome P-450 IVA1 concentra­
tions correlated strongly w ith  the w-hydroxylase activ ity  towards lauric acid in 
these samples (r =  0 .94, p =  0.0001, n = 30) (Fig 3) and did not correlate 
w ith  the (w-D-hydroxylase activ ity (r = 0.17, p = 0.36, n = 30).
Sharma e t al. [13] used the same ELISA procedure and applied a hydroxyla- 
se assay w ith  radiolabelled lauric acid as substrate and found identical results.
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Figure 3 - Plot of immunochemically determined cytochrome P450 4A1 concen- 
trations and w-hydroxylase activities towards lauric acid in microsomal fractions from 
rats treated with DEHP (y = 1.6 + 1.8x, r = 0.94, p = 0.0001, n = 30)
As the determ ination o f lauric acid metabolites was possible in microsomal 
liver samples o f untreated rats, the sensitivity o f the method is suffic iënt 
(signal-to-noise ratio for tv- and (w-1 )-hydroxylauric acid in samples o f the 
untreated rats is >  20). The coëfficiënt of variation (C.V.) based on duplicate 
incubations is 7 .6 .%  for w-hydroxylauric acid (n = 40) and 10% for (a/-1)- 
hydroxylauric acid (n = 40). The Br-mdmc esters o f lauric acid and (w-1)- and 
w-hydroxylauric acid in methanol are stable for at least 2 months when stored 
in the dark at ambient temperature.
Measurement o f lauric acid hydroxylase activ ity based on derivatization of 
the substrate and metabolites w ith  Br-mdmc provides a precise and sensitive 
method for the determination o f lauric acid hydroxylase activities w ithou t the 
need o f using radiolabelled substrates.
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Abstract 
In order to investigate a proposed relationship between induction of 
hepatic microsomal lauric acid hydroxylase activity and peroxisome prolife-
ration in the liver, male Wistar rats were treated with peroxisome prolifera-
ting compounds, and the lauric acid hydroxylase activity, the immunoche-
mical detectable levels of cytochrome P450 4A1 and the activities of per-
oxisomal enzymes were determined. In addition, the levels of cytochrome 
P450 4A1 and lauric acid hydroxylase activities were studied after treat-
ment of rats with three cytochrome P450 inducers. After treatment with 
aroclor-1254, phénobarbital or 3-methylcholanthrene total cytochrome 
P450 was 1.7-2.7 times induced. However, no induction of lauric acid ω-
hydroxylase activities or P450 4A1 levels were found. After treatment of 
rats with di(2-ethylhexyl)phthalate (DEHP) a dose-dependent induction of 
lauric acid ω-hydroxylase activities, levels of cytochrome P450 4A1 and 
peroxisomal fatty acid ^-oxidation was found. Even at a dose-level of 100 
mg DEHP/kg body weight per day a significant induction of these activities 
was observed. The main metabolites of DEHP, mono(2-ethylhexyl)phthala-
te and 2-ethyl-1-hexanol also caused an induction of levels of P450 4A1, 
lauric acid ω-hydroxylase activities and the activity of peroxisomal palmi-
toyl-CoA oxidase. 2-Ethyl-1-hexanoic acid did not influence lauric acid ω-
hydroxylase activities, but did induce levels of P450 4A1 and palmitoyl-
CoA oxidase activities. Three other compounds (perfluoro-octanoic acid, 
valproate and nafenopin) induced both lauric acid ω-hydroxylase activity 
and peroxisomal palmitoyl-CoA oxidase activity. The plasticizer di(2-ethyl-
hexyDadipate, did not induce levels of P450 4A1, lauric acid ω-hydroxylase 
activities or palmitoyl-CoA oxidase activities. With the compounds tested a 
close association between the induction of lauric acid ω-hydroxylase 
activities and peroxisomal palmitoyl-CoA oxidase activity was found. These 
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data support the theory that peroxisome proliferating compounds do induce 
lauric acid ω-hydroxylase activities and that there might be a mechanistic 
inter-relationship between peroxisome proliferation and induction of lauric 
acid ω-hydroxylase activities. 
Introduction 
A large number of chemicals that induce hepatic peroxisome proliferation 
cause the emergence of liver cell carcinoma in lifetime animal assays. This 
group includes highly used hypolipidaemic drugs, like Clofibrate and nafe-
nopin, chlorophenoxyacid herbicides and industrial plasticisers, like di(2-et-
hylhexyDphthalate (DEHP). Chemically, these compounds seem to be a 
heterogenous group, however many of them can be metabolized to a hy­
drophobic backbone with a carboxylic function. Administration of these 
compounds to rodents results in an increase in the number and volume of 
peroxisomes in hepatocytes and also in an increase in the number of cells 
undergoing DNA synthesis (for review: [ 1 , 2]). Peroxisome proliferators 
are called non-genotoxic hepatocarcinogens since they cause liver cell 
carcinoma but fail to cause DNA damage directly [3]. The exact mechanis­
tic relationship of peroxisome proliferation and tumour formation remains 
unknown. 
Proliferation of peroxisomes is proposed to be mediated by an increased 
formation of ω-hydroxy fatty acids due to cytochrome P450 4A1 activity, 
which are converted to dicarboxylic acids in the cytoplasm of hepatocytes 
[4]. Dicarboxylic acids are mainly metabolized by the peroxisomal ^-oxi­
dation system [5,6]. In the metabolism of fatty acids by the peroxisomal 
^-oxidation system hydrogen peroxide is produced. It has been proposed 
that the imbalance between hydrogen peroxide production and degradation, 
results in an oxidative stress and ultimately in DNA damage. Propagation of 
this leasion by the well-documented hyperplastic response to peroxisome 
proliferators might result in liver cell carcinoma [7]. 
After treatment of rats in vivo or hepatocytes of rats in vitro with per­
oxisome proliferators it was shown that RNA encoding cytochrome P450 
4A1 appears prior to RNA encoding peroxisomal enzymes [8,9,10]. Bell et 
al. [9] showed by immunohistochemical staining that cytochrome P450 4A 
and peroxisomal acyl-CoA oxidase were induced in the same region of the 
liver by the peroxisome proliferator methylclofenapate. Cytochrome P450 
4A1, formerly termed cytochrome P452, is a fatty acid hydroxylating 
enzyme (for review: [11]). Medium-chain length (C6-C12) fatty acids are 
oxidized by either of two microsomal pathways, ω- or (ω-11-hydroxylation. 
Tamburini et al. [12] reported that purified cytochrome P450 4A1 in a 
reconstituted enzyme system exhibits a lauric acid ω- and (ω-11-hydro-
xylase activity in a 6:1 ratio. However, Thomas et al. [13] found that 
purified cytochrome P450 4A1 in a reconstituted system only catalyses the 
ω-hydroxylase activity, while an equimolar mixture of 4A2 and 4A3 
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catalyze both ω- and (ω-1 (-hydroxylase activity in a 3:1 ratio. Tanaka et al. 
[14] found that multiple purified cytochrome P450 enzymes have lauric 
acid (ω-U-hydroxylase activities but not ω-hydroxylase activities, so lauric 
acid (ω-1) hydroxylase activity is not specific for cytochrome P450 4A1. 
It was demonstrated that ω-hydroxylase activity towards lauric acid and 
cytochrome P450 4A1 can be induced by xenobiotics like hypolipidaemic 
agents [4], di-(2-ethylhexyl)phthalate (DEHP) [15], chlorophenoxyacid 
herbicides [16] and perfluorinated compounds [17]. DEHP is widely used as 
plasticizer in PVC plastics and is an important environmental pollutant [18]. 
In the body, DEHP is rapidly hydrolysed to mono-(2-ethylhexyl)phthalate 
(MEHP) and 2-ethyl-1-hexanol. 2-Ethyl-1-hexanol can be further oxidized to 
2-ethyM-hexanoic acid [19]. 2-Ethylhexanoic acid is also used as a wood 
preservative agent. 2-Ethyl-1-hexanol, 2-ethyl-1-hexanoic acid, the plastici­
zer di(2-ethylhexyl)adipate (DEHA), the epileptic drug valproate and perfluo-
rooctanoic acid enhance peroxisomal ^-oxidation enzymes but the effects 
on cytochrome P450 4A1 and its associated lauric acid ω-hydroxylase 
activity have not been reported yet [20-23]. Studies on the effects of other 
cytochrome P450 inducers on lauric acid hydroxylase activities have been 
limited to phénobarbital, 3-methylcholanthrene and aroclor 1254. Since 
different effects were found we have repeated these studies and in addition 
we have quantified the levels of immunochemical detectable P450 4A1. 
In this paper we further studied the relationship between induction of 
microsomal lauric acid ω-hydroxylase activity and peroxisomal palmitoyl-
CoA oxidase activity by testing a number of chemicals, known to induce 
peroxisomal ß-oxidation, on their ability to induce lauric acid ω-hydroxylase 
activities and cytochrome P450 4A1. 
Materials and methods 
Chemicals and reagents 
Nafenopin was a gift of Ciba Geigy (Basle, Switzerland). Valproate 
(2-propylpentanoic acid), 3-methylcholanthrene, lauric acid, ω-hydroxylauric 
acid, NADPH, palmitoyl-CoA, acetyl-CoA and aminotriazole were obtained 
from the Sigma Chemical Co. (St. Louis, MO, U.S.A.). 2,7-Dichlorofluor-
escin diacetate was purchased from Eastman Kodak Co. (Rochester, NY, 
U.S.A.). DEHP, DEHA and 2-ethyl-1-hexanol were obtained from Janssen 
Chimica (Beerse, Belgium). 2-Ethyl-1-hexanoic acid, 18-crown-6 ether and 
4-(bromo-methyl)-6,7-dimethoxycoumarin (Br-mdmc) were obtained from 
the Aldrich Chemical Co. (Milwaukee, Wl, U.S.A.). Perfluoro-octanoic acid 
was from Lancaster Synthesis Ltd. (Morecambe, UK). Aroclor-1254 was 
from Alltech Associated, Inc. (Deerfield, III, U.S.A.) and phénobarbital was 
obtained from OPG (Utrecht, The Netherlands). 
MEHP was synthesised by refluxing phthalic anhydride (14.8 g) and 
2-ethyl-1-hexanol (13 g) in 20 mL toluene for 2 hr in the presence of 15 
mg 4-dimethylaminopyridine. The toluene was distilled off and the product 
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was dissolved in diethylether and extracted into 0.5M K2C03. The product 
was released for extraction into diethylether by acidification with 2M 
KHSO4. The product was 9 9 % pure and the structure was confirmed by 
NMR and Mass Spectrometry. 
Antibodies against cytochrome P450 4A1 were a generous gift of Dr. G. 
Gordon Gibson, University of Surrey, Guildford, U.K. All other chemicals 
were of the highest purity obtainable. 
Animals and treatment 
Male random-bred Wistar rats (Cpb:WU {SPF)), body wt 175-225 g) 
were maintained at 23-25 °C with an alternating 12-hr light and dark cycle 
and with free access to RMH food pellets (Hope Farms, Woerden, The 
Netherlands) and water. For the treatment with 3-methylcholanthrene male 
random bred Wistar rats (Bor:WIS (SPF)), body wt 350 g) were used . 
Rats were treated i.p. with aroclor-1254 in olive oil (500 mg/kg body wt) 
or with olive oil (2 mL/kg body wt). Five days after the aroclor-1254 treat-
ment the rats were killed by decapitation. Rats were treated i.p for 4 days 
with phénobarbital in saline (75 mg/kg body wt) or with saline (1 mL/kg 
body wt) and with 3-methylcholanthrene in olive oil (25 mg/kg body wt) or 
with olive oil (0.6 mL/kg body wt). Twenty four hours after the last dose 
rats were killed. All the next doses are expressed as mg/kg body wt per 
day. In brackets is the dose expressed as mmol/kg body wt per day. Rats 
were pretreated by gastric intubation once a day for 3 days with DEHP 
(dose levels: 50 (0.13), 100 (0.26), 250 (0.64), 500 (1.28) and 1000 
(2.6) mg/kg; MEHP (250 (0.9) mg/kg); DEHA (475 (1.3) mg/kg); 2-ethyl-1-
hexanol (500 (3.8) mg/kg); 2-ethyl-1-hexanoic acid (550 (3.8) mg/kg); 
valproate (550 (3.8) mg/kg); nafenopin (100 (0.3) mg/kg) and perfluoro-oc-
tanoic acid (50 (0.1) mg/kg). Five to seven animals were used per group. 
Olive oil was used as a vehicle for administration. Control animals were 
given olive oil at 5 mL/kg body wt per day. One group of five rats was 
pretreated by gastric intubation with saline. Twenty four hours after the 
last dose, animals were weighted and then killed by decapitation prior to 
perfusion of the livers. 
Preparation of liver fractions 
Livers were perfused with 0.9% NaCI (w/w) for 10 min. Entire livers 
were removed and weighed. Whole liver homogenates (20% w/v) were 
prepared in 0.25M sucrose, 2 mM EDTA and 10 mM Tris-HCI (pH 7.4) 
(SETH buffer) using a teflon-glass homogeniser. A part of this homogenate 
was freeze/thawed three times, followed by centrifugaron at 9,000g for 5 
min. The supernatants were flash frozen in liquid nitrogen and stored at 
-80°C until they were thawed for enzymatic analysis of palmitoyl-CoA 
oxidase- and carnitine acetyltransferase activity. 
The remaining part of the whole liver homogenate was centrifuged at 
9,000g for 20 minutes and the supernatant was centrifuged at 105,000g 
for 1 hr. The pellet (microsomal fraction) was homogenized in SETH buffer 
and aliquots were flash frozen in liquid nitrogen and stored at -80°С until 
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Table 2 - The effect of DEHP on liver size, cytochrome P450 and cytochrome 
P450 4A1. 
dose 
0 
50 
100 
250 
500 
1000 
liver/ 
body weight 
ratio 
4.8 ± 0.4 
5.1 ± 0.3 
5.2 ± 0.4 
5.6 ± 0.5° 
5.7 ± 0.4° 
5.8 ± 0.2° 
total 
cytochrome 
P450 
(nmol/mg 
protein) 
0.55 ± 0.08 
0.64 ± 0.1 
0.64 ± 0.1 
0.59 ± 0.06 
0.69 ± 0.1 
0.71 ± 0.1 
specific cytochrome P450 4A1 
nmol/mg 
protein 
0.013 ± 0.005 
0.032 ± O.OT 
0.049 ± 0.01 * 
0.069 ± 0 . 0 1 * 
0.094 ± 0.03* 
0.109 ± 0.03* 
% of total 
cyt. P450 
2.4 ± 0.9 
4.9 ± 0.9° 
7.7 ± 1.4° 
10.9 ± 1.4° 
13.5 ± 2.4° 
15.4 ± 0.6° 
values are means ± SD of 5-7 rats. 
* = statistically different from control ρ < 0.05 (ANOVA and Dunnett's test) 
° = statistically different from control ρ < 0.05 (Mann-Whitney U test with 
Bonferroni correction) 
they were thawed for determination of cytochrome P450 content, cyto­
chrome P450 4A1 concentration and lauric acid hydroxylase activity. 
Other methods 
Palmitoyl-CoA oxidase activity was determined according to Reubsaet et 
al. [24]. Carnitine acetyltransferase was determined at 2 5 ° C according to 
Gray et al. [25]. Lauric acid hydroxylase activities were determined by 
reverse phase HPLC and fluorimetrie detection based on the derivatization 
of lauric acid and its metabolites with the fluorescent compound Br-mdmc 
as previously presented elsewhere [26]. Total cytochrome P450 was 
determined from the СО-difference spectrum by the method of Omura and 
Sato [27]. Cytochrome P450 4A1 was determined immunochemically by an 
ELISA method described by Sharma et al. [4]. On immunoblots the antibo­
dies react with two protein bands (51.5 and 52 kDa). The 51.5 kDa protein 
co-migrates with authentic rat cytochrome P450 4 A 1 , the 52 kDa band is 
probably 4A2 or 4A3 [28]. Protein concentrations were determined by the 
method of Bradford [29] using crystalline bovine serum albumin as stand­
ard. 
Statistical analysis 
Data were analysed using SAS-software, version 6. All tests performed are 
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two tailed. 
Results 
Studies with classical cytochrome P450 inducers 
The effects of phénobarbital, 3-methylcholanthrene and aroclor-1254 
administration on total cytochrome P450 content, the specific cytochrome 
P450 4A1 levels and lauric acid (ω-D- and ω-hydroxylase activities are 
summarized in table 1. 
All compounds tested increased the total cytochrome P450 content of 
liver microsomes (1.7-2.7 times). Specific cytochrome P450 4A1 levels in 
control animals as determined by ELISA were shown to be 1.8 to 2.2% of 
total cytochrome P450, and no induction of cytochrome P450 4A1 by 
phénobarbital, 3-methylcholanthrene or aroclor-1254 was observed. When 
the levels of P450 4A1 were expressed as percentage of total cytochrome 
P450 all 3 compounds decreased the P450 4A1 content. Furthermore no 
induction was found of the ω-hydroxylase activity towards lauric acid, the 
marker substrate for cytochrome P450 4A1, when this activity was 
expressed per mg protein. When this activity was expressed per nmol P450 
a decrease was found. A 2-fold increase in the (ω-1 (-hydroxylase activity 
was found after aroclor-1254 and phénobarbital treatment when this 
activity was expressed per mg protein. No increases were found when the 
(ω-1 (-hydroxylase activity was expressed per nmol P450. We prefer this 
latter expression because it is possible that total cytochrome P450, inclu­
ding P450 4A1 levels and lauric acid hydroxylase activities, is induced by 
the test compound, which can obscure the specific induction of lauric acid 
hydroxylase activities. 
Our results clearly show that classical enzyme inducers used in toxicolo-
gical studies such as phénobarbital, 3-methylcholanthrene or aroclor-1254 
do not induce lauric acid hydroxylase activities or cytochrome P450 4A1. 
Dose-response studies with DEHP 
The effect of DEHP administration on liver/body weight ratio, total cyto-
chrome P450 content and specific cytochrome P450 4A1 isoenzyme levels 
are shown in table 2. In rats receiving DEHP doses of more than 250 mg/kg 
body weight per day a significant hepatomegaly was found. Total cytochro-
me P450 levels were not altered by the DEHP treatment. Following DEHP 
treatment ¡mmunochemically determined cytochrome P450 4A1 con-
centrations were strongly increased in a dose-dependent manner. Even at 
the lowest DEHP dose (50 mg/day per kg body weight) a 2-fold induction 
of cytochrome P450 4A1 was found. At dose levels of 100 mg DEHP/kg 
body weight per day or higher, the associated cytochrome P450 4A1-dri-
ven lauric acid ω-hydroxylase activity was induced in a dose-dependent 
manner (figure 1a). At dose-levels of 500 or 1000 mg DEHP/kg body 
weight per day this activity was increased 8-9 fold. No increase in the lauric 
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Figure 1 - Effect of DEHP on lauric acid hydroxylase activities (A), peroxisomal 
palmitoyl-CoA oxidase activities (В) and carnitine acetyltransferase activities (C). 
Each bar represents the mean ± SD of 5-7 rats. 
Щ = (ω-D-hydroxylauric acid and xf|= ω-hydroxylauric acid 
• Statistically different from control ρ < 0.05 (ANOVA and Dunnett's test) 
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Table 3 - The effect of DEHP and metabolites of DEHP on liver size, cytochrome P450 
and cytochrome P450 4A1. 
treatment 
Control 
DEHP 
MEHP 
2-ethyl-1-hexanol 
2-ethyl-1-hexanoic 
acid 
dose 
(mmol/kç 
body 
weight) 
. 
1.3 
0.9 
3.8 
3.8 
liver/ 
I body 
weight 
ratio 
5.0 ± 0.2 
5.9 ± 0.4° 
5.6 ± 0.8 
5.4 ± 0.3 
5.8 ± 0.4 
total 
cytochrome 
P450 
(nmol/mg protein) 
0.69 ± 0.1 
0.96 ± 0.16· 
0.76 ± 0.05 
0.73 ± 0.07 
0.77 ± 0.09 
specific cytochrome P450 4A1 
nmol/mg % of total 
protein cyt. P450 
0.011 ± 0.005 1.6 ± 0.7 
0.129 ± 0.03* 13.5 ± 1.8e 
0.084 ± 0 . 1 * 11.0 ± 1.6° 
0.037 ± 0.01* 5.1 ± 1.2e 
0.033 ± 0.005' 4.3 ± 0.7° 
values are means ± SD of 5-7 rats. 
* = statistically different from control ρ s 0.05 (ANOVA and Dunnett's test) 
° = statistically different from control ρ £ 0.05 (Mann-Whitney U test 
with Bonferroni correction) 
acid (ω-D-hydroxylase activity was found. Acyl-CoA oxidase activity is 
rate-1 i m iti η g in the peroxisomal ß-oxidation and it was shown that pal-
mitoyl-CoA oxidase was the most sensitive marker for peroxisome 
proliferation in the liver [30]. At dose levels of 100 mg DEHP/kg body wt 
per day or higher palmitoyl-CoA oxidase activities were dose-relatedly 
induced by the DEHP treatment (figure 1b). It has been reported that the 
increase in number and size of peroxisomes in rats treated with peroxisome 
proliferators correlates well with increased carnitine acetyl-CoA oxidase 
activity, although it is not a specific peroxisomal enzyme [4]. At dose levels 
of 100 mg DEHP/kg body wt per day or higher carnitine acetyl transferase 
activity also exhibits a dose-dependent increase following the administra-
tion of DEHP (figure 1c). A dose of 100 mg DEHP/kg body wt per day 
gives an increase in both peroxisomal enzyme activities and of lauric acid 
ω-hydroxylase activities. This dose-level is 2.5 times lower than in an 
another study [15]. 
Studies on DEHP metabolites 
The effects of the metabolites MEHP, 2-ethyl-1-hexanol and 2-ethyl-1-
hexanoic acid were compared with the effects of DEHP. Administration of 
DEHP did result in a liver enlargement and in an increase in the total 
cytochrome P450 content of the liver microsomes (table 3). DEHP, MEHP, 
2-ethyl-1-hexanol and 2-ethyl-1-hexanoic acid increased cytochrome P450 
4A1 levels (table 3). None of the compounds altered lauric acid (ω-D-
hydroxylase activities, while DEHP, MEHP and 2-ethylhexanol resulted in a 
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nmol product/min.nmol cytochrome P450 
control DEHP MEHP ethyl-hexanol hexanoic acid 
nmol hydrogenperoxide/min.mg protein 
control DEHP MEHP
 e , h y | _ ethyl-
hexanol hexanoic acid 
Figure 2 - Effect of DEHP, MEHP, 2-ethyl-1-hexanol and 2-ethyl-1 -hexanoic acid 
on lauric acid hydroxylase activities (A) and peroxisomal palmitoyl-CoA oxidase 
activities (B). 
Each bar represent the mean ± SD of 5-7 rats. 
B = (ω-D-hydroxylauric acid and Щ = ω-hydroxylauric acid 
* Statistically different from control ρ < 0.05 (ANOVA and Dunnett's test). 
Palmitoyl-CoA oxidase activitity, a marker for peroxisome proliferation was 
increased by all four compounds tested (figure 2b). 
Studies on other compounds possible having a peroxisome proliferating 
action 
Effects of administration of valproate, perfluoro-octanoic acid and DEHA 
to rats were compared with the well known effects of the peroxisome 
proliferator nafenopin. Administration of perfluoro-octanoic acid and 
nafenopin resulted in a hepatomegaly (table 4). Perfluoro-octanoic acid was 
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Table 4 - The effect of olive oil, saline, DEHA, valproate, perfluoro-octanoic acid and nafenopin 
on liver size, cytochrome P450 and cytochrome 4A1. 
Treatment 
olive oil 
saline 
DEHA 
valproate 
perfluoro-
octanoic acid 
nafenopin 
dose 
(mmol/kg 
body 
weight) 
-
1.3 
3.8 
0.1 
0.3 
liver/ 
body 
weight 
ratio 
5.0 ± 0.2 
4.9 ± 0.3 
5.0 ± 0.4 
5.5 ± 0.5 
7.1 ± 0.5 e 
6.8 ± 0.8° 
total 
cytochrome 
P450 
(nmol/mg 
protein) 
0.69 ± 0.1 
0.74 ± 0.1 
0.67 ± 0.1 
0.74 ± 0.1 
1.69 ± 0.3* 
0.71 ± 0.07 
specific cytochrome P450 4A1 
nmol/mg 
protein 
0.011 ± 0.005 
0.009 ± 0.002 
0.014 ± 0.003 
0.039 ± 0.007* 
0.199 ± 0.03* 
0.133 ± 0.02* 
% of total 
cyt. P450 
1.63 ± 0.7 
1.21 ± 0.4 
2.14 ± 0.4 
5.29 ± 0.4° 
11.86 ± 1.7° 
18.76 ± 1.6" 
values are means ± SD of 5-7 rats. 
* = statistically different from control ρ s 0.05 (ANOVA and Dunnett's test) 
° = statistically different from control ρ < 0.05 (Mann-Whitney U test with 
Bonferroni correction) 
also able to increase the total cytochrome P450 level 2.5 times. Perfluo­
ro-octanoic acid, valproate and nafenopin induced levels of cytochrome 
P450 4A1 (3-11 fold). These three compounds also increased the ω-hydro­
xylase activity towards lauric acid 3-11 fold, but only nafenopin increased 
the lauric acid (ω-11-hydroxylase activity (figure 3a). Palmitoyl-CoA oxidase 
activities were induced in the liver of rats treated with these compounds. 
No (significant) increase in cytochrome P450 4A1 levels, in the ω-hydroxy­
lase activity towards lauric acid or palmitoyl-CoA oxidase activities were 
found after the DEHA treatment (figure 3b). 
It was reported that high fat diets also produce lauric acid ω-hydroxylase 
activity induction [31]. Therefore, we studied a possible bias in our experi­
ments of olive oil, which was the vehicle in most of our experiments. A 
group of rats treated once a day by gastric intubation for 3 days with olive 
oil was compared with a group of rats treated with saline. No differences 
were found in total cytochrome P450 concentrations, cytochrome P450 
4A1 levels (table 4), or in hydroxylase activities towards lauric acid and pal-
mitoyl-CoA oxidase activities (figure 3a and 3b) between the olive oil or the 
saline treated group. The vehicle used in our experiments appeared to have 
no effect on the parameters studied. 
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Figure 3 - Effect of olive oil, saline, DEHA, valproate, nafenopin and perfluoro-
octanoic acid on lauric acid hydroxylase activities (A) and peroxisomal palmitoyl-
CoA oxidase activities (B). Each bar represents the mean of 5-7 rats. 
H = (ω-1 (-hydroxylauric acid and J§§= ω-hydroxylauric acid. 
• Statistically different from control ρ s 0.05 (ANOVA and Dunnett's test) 
Discussion 
None of the classical P450 inducers tested increased cytochrome P450 
4 Α Ί levels or the ω-hydroxylase activity towards lauric acid. The results 
obtained w i t h aroclor-1254 are in contrast with the results of Borlakoglu et 
at. [32] who reported a 5-fold increase in the formation of ω-hydroxylauric 
acid, expressed per mg protein, in the liver of female rats treated with 
aroclor-1254. Since we have used male rats in our experiments, the ob­
served differences in inducibility of the ω-hydroxylase activity towards 
lauric acid after aroclor-1254 treatment might be due to sex differences. 
Comparisons of our data with the data of others is somewhat complica­
ted because lauric acid hydroxylase activities are by some authors expres-
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sed per mg protein and by others per nmol cytochrome P450. We found a 
2-fold increase of (ω-1 (-hydroxylase activity in the livers of rats treated 
with aroclor-1254 and phénobarbital, when the activity is presented per mg 
protein, but no increase was found when the activity was expressed per 
nmol cytochrome P450. Similar increases in lauric acid (ω-1 (-hydroxylase 
activities (when expressed per mg protein) after phénobarbital treatment 
were also found by Okita and Masters [33] and Cresteil et al. [34] . Tanaka 
et al. [14] found that both activities are decreased after phénobarbital 
treatment when these activities were expressed per nmol P450. After 3-
methylcholanthrene treatment we found a decrease in both ω- and (ω-1(-
hydroxylase activities when this activity was expressed per nmol P450. 
Similar findings were reported by Tanaka et al. [14]. We found no differ­
ences between the t w o activities when the activity was expressed per mg 
protein, but Cresteil et al. [34] found a decrease. Taken collectively our 
data and the data of others [14, 33, 34] make clear that phénobarbital and 
3-methylcholanthrene do not induce lauric acid ω-hydroxylase activities or 
levels of immunochemical detectable P450 4 A 1 . These findings are suppor­
ted by the recent finding that levels of RNA levels encoding t w o other 
members of the cytochrome P450 4A family (cytochrome P450 4 A 2 and 
4A3) were increased in rats after treatment with Clofibrate, but not after 
treatment wi th the P450 inducers phénobarbital, 3-methylcholanthrene and 
dexamethasone [35]. 
Recent studies with hypolipidaemic peroxisome proliferators, w i th 
chlorinated phenoxy acid herbicides and with perfluorinated compounds 
have demonstrated an excellent correlation between microsomal cytochro-
me P450 4A1 and its associated lauric acid ω-hydroxylase activity on the 
one hand, and peroxisomal volume and peroxisomal ß-oxidation activity on 
the other in the liver of rats [4, 16, 17]. After treatment of rats wi th 
different doses of DEHP we found a dose-related increase in cytochrome 
P450 4A1 levels and its associated lauric acid ω-hydroxylase activity, as 
well as peroxisomal enzymes like palmitoyl-CoA oxidase and carnitine 
acetyl transferase. This is in close agreement with data presented by 
Sharma et al. [ 1 5 ] , although we have used 2.5 times lower dose levels. In 
most studies DEHP is administered to rats as part of the diet. The lowest 
dose of DEHP used in our study which induced both lauric acid ω-hydroxy­
lase- and palmitoyl-CoA activity is equal to a diet containing 0 . 1 % DEHP 
(calculated on basis of previously published data [36]) and this dose is one 
of the lowest doses which has been reported to induce palmitoyl-CoA 
oxidase activities and lauric acid ω-hydroxylase activities. 
When the DEHP metabolites MEHP, 2-ethyl-1-hexanol and 2-ethyl-l-
hexanoic acid were administrated orally to rats, an induction of the levels 
of P450 4 A 1 was found. MEHP and 2-ethyl-1-hexanol, but not 2-ethyl-1-
hexanoic acid increased the lauric acid ω-hydroxylase activity. All three 
compounds induced peroxisomal palmitoyl-CoA oxidase. 
Another plasticizer, DEHA was also reported to enhance peroxisomal ß-
oxidation activity [20]. With the dose level used in our study, DEHA gave 
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Figure 4 - Association between palmitoyl-CoA oxidase activities and lauric acid w-
hydroxylase activities after treatment of rats with DEHP (500 mg/kg per day), 
MEHP, 2-ethyl-1-hexanol, 2-ethyl-1-hexanoic acid, nafenopin, valproate, perfluoro-
octanoic acid, DEHA and olive oil. Of each group mean values were used, 
(y = 0.88 + 0.15X, r = 0.91, η = 9). 
hydroxylase activity. 
Our results also indicate that the anti-epileptic drug valproic acid, a 
chemical analogue of the DEHP metabolite 2-ethylhexanoic acid, and 
perfluoro-octanoic acid are inducers of cytochrome P450 4 A 1 and lauric 
acid ω-hydroxylase activities. The strong inducibility of peroxisome prolife­
ration by perfluorinated fatty acids is unexpected because the structures of 
these chemicals are dissimilar from any known peroxisome proliferating 
compounds. Owing to their metabolically inert properties these compounds 
may be proximate inducers themselves. 
The data obtained in the experiments with DEHP (500 mg/kg per day), 
2-ethyl-1-hexanoic acid, 2-ethyl-1-hexanol, MEHP, DEHA, nafenopin, 
valproate and perfluoro-octanoic acid were used to study the correlation of 
biological effects of peroxisome proliferating compounds on the liver. A 
correlation matrix is shown in table 5. Total cytochrome P450 did not 
correlate well wi th palmitoyl-CoA oxidase activities. A high correlation was 
found between P450 4A1 levels, and its associated lauric acid ω-hydroxyla­
se activities and peroxisomal palmitoyl-CoA oxidase activities. The high 
degree of association between palmitoyl-CoA oxidase activity and lauric 
acid ω-hydroxylase activity is also shown in figure 4. Although cause and 
effect can not be separated by a correlation analysis, our data and data 
from others [ 4 , 17] are suggestive of a mechanistic interrelationship 
between induction of lauric acid ω-hydroxylase activity by P450 4A1 and 
peroxisome proliferation. 
In conclusion: the induction of cytochrome P450 4A1 and its associated 
lauric acid ω-hydroxylase activity seems to be specific for peroxisome 
proliferating compounds. Determination of levels of P450 4A1 and lauric 
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acid ω-hydroxylase activities in identifying peroxisome prohferators is very 
useful since these parameters are very sensitive. The demonstration of the 
ability of several peroxisome proliferating compounds to induce cytochrome 
P450 4A1 further support the hypothesis that there might be a mechanistic 
interrelationship between peroxisome proliferation and induction of lauric 
acid ω-hydroxylase activities. 
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Introduction 
Cytochrome P-450 enzymes are important in the metabolism of many 
endogenous substrates, as well as a large variety of drugs, chemical 
carcinogens, and environmental pollutants. Ten families of cytochrome 
P-450 enzymes have been identified so far in mammals [1]. Six of these are 
small families of one or two members and are involved in pathways of 
steroidogenesis or bile acid synthesis in highly specialized tissues [2]. One 
family, cytochrome P-450 IV, consists of enzymes that are involved in 
hydroxylating fatty acids [2]. The remaining three families encode xenobiotic 
metabolizing enzymes. In these latter four families, it appears that a 
tremendous variability exists between species in the number of P450 genes 
and the substrate specificities of individual P450 forms [2]. It is therefore 
difficult to extrapolate toxicology and carcinogenicity studies from rodents to 
man. These species differences emphasize the necessity to study human 
cytochrome P450 enzymes. 
One of the most active cytochrome P450 IV fatty acid-metabolizing 
enzymes is P450 IVA1, formely termed cytochrome P452 [3-5]. The 
ω-hydroxylase activity towards lauric acid is suggested to be an indicator of 
P-450 IV activity [2,3,5]. After treatment of rats with hypolipidaemic, 
peroxisome proliferating compounds like Clofibrate, nafenopin or 
di(2-ethylhexyl)phthalate (DEHP) both the ω-hydroxylase activity towards 
lauric acid, and cytochrome P-450 IVA1 protein content are substantially 
induced in liver and kidney, whereas the («/-D-hydroxylase activity is much 
less induced [5-8]. 
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Since the hypolipidaemic, peroxisome proliferating compounds are classified 
as epigenetic hepatocarcinogens [9, 10], attention has been focussed to 
elucidate the possible mechanism(s) of carcinogenesis. It has been suggested 
that the carcinogenicity might result from an increased hydrogen peroxide 
production generated via the peroxisomal fatty acid ^-oxidation in the liver 
[10] . Sharma et al. (1988) proposed that the enhanced peroxisomal ß-
oxidation is a result of the perturbation of lipid metabolism, which in turn 
might be the result of an enhanced ω-hydroxylation of fatty acids by 
cytochrome P450 I V A 1 . 
Species differences in peroxisome proliferation have been reported. Non-
rodent species are reported to be less sensitive to peroxisome proliferators 
than rodents [11-13]. Since peroxisome proliferation is causally linked to 
hepatocarcinogenicity there is considerable debate about the significance of 
peroxisome proliferators as hepatocarcinogens in humans. More information 
regarding the cause of the interspecies differences of peroxisome proliferation 
is needed. 
It seems possible that species differences in peroxisome proliferation are 
the result of differences in the presence or inducibility of cytochrome P450 
IVA1 [11-13]. In this paper we have studied the presence of cytochrome 
P450 IV family enzymes in hepatic microsomes derived from human samples, 
as a preliminary step in determining the potential human risk posed by 
peroxisome proliferators. 
Materials and Methods 
Chemicals and reagents 
Nafenopin was a gift of Ciba Geigy (Basle, Switzerland). Laurie acid, 
ω-hydroxylauricacid and NADPH were obtained from the Sigma Chemical Co. 
(St. Louis, MO, U.S.A.). 18-Crown-6 ether and 4-(bromomethyl)-6,7-
dimethoxycoumarin were obtained from the Aldrich Chemical Co. (Milwaukee, 
Wl , USA). DEHP was purchased from Janssen Chimica (Beerse, Belgium). 
Antibodies against a highly purified, electrophoretically homogenous 
preparation of rat hepatic cytochrome P450 IVA1 were raised in sheep and 
the specificity of the antibodies is described elsewhere [6,7] . All other 
chemicals were of the highest purity obtainable. 
Liver samples 
Human liver samples were obtained from kidney transplant donors (n = 13). 
The investigations were approved by the local ethical committee on human 
experimentation. 
Rat liver samples were from male random-bred Wistar rats (Cbp:WU (SPF)), 
body w t 150-200 g). Rats were pretreated by gastric intubation once daily for 
3 days wi th either di(2-ethylhexyl)phthalate (500 mg/kg body w t ) , nafenopin 
( 100 mg/kg body w t ) , olive oil (5 mL/kg body wt) or saline. Twenty-four hours 
after the last dose rats were killed by decapitation. Livers were perfused with 
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0.9% (w/w) NaCI; for 10 min. 
Whole liver homogenates were prepared in 0.25M sucrose/2 m M EDTA and 
10 m M Tris/HCI (pH 7.4). Homogenate was centrifuged at 10,000g for 20 
min. Microsomal fractions were prepared from the 10,000g supernatant by 
centrifugation at 105,000g for 60 min. 
Assays 
The ω- and (ω-1 (-hydroxy metabolites of lauric acid were separated by 
reverse phase HPLC after derivatization with the fluorescent compound 
4-(bromomethyl)-6,7-dimethoxycoumarin, as described by Dirven et al. [ 8 ] . 
Total cytochrome P-450 content was determined by the method of Omura and 
Sato [14] . 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis fol lowed by 
immunoblotting with a polyclonal antibody against rat hepatic cytochrome 
P-450 IVA1 was performed according to Peters and Jansen [ 1 5 ] . A 
semi-quantitative estimate of the intensity of the cytochrome P-450 IV bands 
on the immunoblot was made using a laser densitometer (Ultrascan XL, LKB, 
Bromma, Sweden). Protein concentrations were determined by the method of 
Bradford [ 1 6 ] . 
Results and discussion 
Table 1 gives the lauric ω- and (ω-1 (-hydroxylase activities in microsomal 
preparations derived from either human or saline-treated rat liver. The 
activities determined in human liver are 2-4 higher than those measured in rat 
liver. Also the ratios between ω- and (ω-1 (-hydroxylase activities are different 
in rat as compared to man: in man, the ω-hydroxylase activity is twice as large 
as the (w-D-hydroxylase activity, whereas in rat both activities are 
comparable. 
Immunoblot analysis of human and rat microsomal fractions was performed 
using a sheep polyclonal antibody raised against purified rat hepatic 
cytochrome P450 I V A 1 . Figure 1 shows that this antibody reacts wi th t w o 
protein bands (molecular weights 51.5 and 52 KDa) for olive oil-, DEHP- or 
nafenopin-treated rat liver microsomes. This pattern is identical as described 
by Makowska et al. [7] and Hardwick et al. [4]. Both bands are induced by the 
treatment w i t h either DEHP or nafenopin. The lower band (51.5 KDa) 
co-migrates w i t h rat hepatic P450 IVA1. The additional band of approximately 
52 KDa might be another member of the P450 IV subfamily [ 7 ] , like 
cytochrome P450 IVA2 or P450 IVA3 [ 1 7 ] , but this has to be verified. 
In all human liver samples a strong and a weak reacting band was detected. 
The strong reacting band has a slightly lower molecular weight (approximately 
51 KDa) than rat hepatic cytochrome P450 I V A 1 . The weak reacting band has 
a molecular weight of approximately 56.5 kDa. These findings suggest the 
existence of proteins in human liver that are immunochemically related to rat 
hepatic cytochrome P-450 I V A 1 . A correlation was found between the 
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Table 1 - w- and (w-D-hydroxylase activities towards lauric acid in human and rat 
liver microsomes.
Hydroxylase acitivity Intensity of
Total (nmol product/min. 51 kDa band
cytochrome nmol total cyt. P450) (absorbance
P450 units/pmol
Patients (nmol/mg (ui-1 )-hydroxy- w-hydroxy- total
No. Sex Age protein) lauric acid lauric acid cyt. P450)
1 F 30 0.24 1.83 2.53 ND
2 F 18 0.78 1.15 1.85 0.15
3 - - 0.51 0.70 2.14 0.15
4 M 27 0.26 1.24 2.87 0.13
5 M 15 0.33 1.55 1.82 0.10
6 M 20 0.34 0.33 2.39 0.16
7 M 46 0.84 1.38 2.16 0.07
8 . - 0.27 1.89 4.08 0.08
9 M 18 0.39 2.25 4.99 0.06
10 - - 0.50 1.15 2.8 0.06
11 - - 0.42 2.32 3.79 0.12
12 M 47 0.20 3.29 4.5 ND
13 F 18 0.26 2.25 4.57 0.08
Mean ± SD 0..41 ±  0.20 1.64 ±  0.78 3.11 ± 1.12
Rats
Mean ± SD1 0..74 ± 0.16 0.66 ±  0.11 0.74 ±  0.49
ND, not determined.
-, Sex and age of these donors are not known. 
1 Mean ±  SD of five rats treated with saline
staining intensities o f the 51.5 kDa band and the rate o f lauric acid uj- 
hydroxylation for the treated and untreated rat samples (see te x t figure 1). 
However, an observable correlation was not found between the staining 
intensities o f the 51 kDa band and the rate o f lauric acid w -hydroxylation for 
the human samples, suggesting that the 51 kDa protein has hardly any lauric 
acid w-hydroxylase activ ity.
Apart from  cytochrome P450IVA1 other cytochrome P450 IV families may 
have lauric acid a/-hydroxylase activ ity [2 ,5 ], and it is possible tha t tha t these 
enzymes catalyse the pronounced lauric acid hydroxylation activ ities, as 
determined in the human liver samples. In addition it should be notified, when
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Figure 1 - Immunodetection of hepatic cytochrome P450IV proteins in rat and human 
liver microsomes. Microsomal fractions were subjected to SDS-polyacrylamide gel 
electrophoresis (7% acrylamide) and immunoblotted with an antibody to rat hepatic 
cytochrome P450 IVA1.
A: Track 1, nafenopin-treated rat liver microsomes [2 pmol]’ ; track 2, DEHP-treated 
rat liver microsomes [2 pmol]2; track 3, olive oil-treated rat liver microsomes [5 
pmol]3; track 4, authentic rat hepatic cytochrome P450 IVA1 Standard [6 pmol].
B: Track 1-5, human liver microsomes corresponding to patients Nos. 13, 10, 9, 8 
and 7, respectively [5 pmol]; track 6, authentic rat cytochrome P450 IVA1 [6 pmol]; 
track 7-12, human liver microsomes corresponding with patients Nos. 6, 5 ,4 ,3, 2 
and 11, respectively [5 pmol]. Amounts of microsomes loaded onto the gel are 
expressed as pmol total cytochrome P450, and is given in brackets.
1 Lauric acid w-hydroxylase activity is 8.35 nmol/min.nmol cytochrome P450 and 
intensity of 51.5 KDa band is 0.55 absorbance units/pmol. 2 Lauric acid w- 
hydroxylase activity is 4.07 nmol/min.nmol cytochrome P450 and intensity of 51.5 
KDa band is 0.32 absorbance units/pmol.3 Lauric acid w-hydroxylase activity is 0.70 
nmol/min.nmol cytochrome P450 and intensity of 51.5 KDa band is 0.05 absorbance 
units/pmol.
analysing human cytochrome P450 IV enzymes by using an antibody raised 
to  rat hepatic cytochrome P450 IVA1, the human cytochrome P450 IV levels 
may be underestimated due to lack o f specificity o f the antibody for the 
human cytochrom e P-450 IV proteins.
We conclude that in human liver cytochrome P450 IV proteins are present, 
which are related to  rat hepatic cytochrome P450 IVA1, but have different
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physicochemical properties. As a consequence, the reported species 
differences in peroxisome proliferation between rodents and primates [11-13] 
might be due to differences in the inducibility of these proteins. 
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Abstract 
Primary hepatocyte cultures derived from rat, rabbit, guinea pig and monkey, 
have been treated in vitro wi th metabolites of di(2-ethylhexyl)phthalate 
(DEHP), i.e. mono(2-ethylhexyl)phthalate (MEHP), mono(5-carboxy-2-
ethyl)pentylphthalate (metabolite V) and mono(2-ethyl-5-oxo-hexyl)-phthalate 
(metabolite VI). In rat hepatocyte cultures MEHP and metabolite VI were 
equally potent in inducing peroxisome proliferation, while metabolite V was 
much less potent. In rat hepatocytes a 5 0 % increase in both peroxisomal 
palmitoyl-CoA oxidase activity and microsomal lauric acid ω-hydroxylation 
activity, was found after treatment with 5-15 μΜ MEHP. In guinea pig, rabbit 
and monkey hepatocyte cultures, a 5 0 % increase in peroxisomal palmitoyl-
CoA oxidase activity was found after treatment with 408-485 μΜ MEHP. No 
induction of lauric acid ω-hydroxylation activity was found. These results 
indicate that peroxisome proliferation can be induced by MEHP in rabbit, 
guinea pig and monkey hepatocytes, but that these species are at least 30-
fold less sensitive for peroxisome proliferation than rats. The proposed 
mechanistic inter-relationship between induction of lauric acid ω-hydroxylation 
activity and peroxisome proliferation, is found in rat hepatocytes, but not in 
hepatocytes of the other three species. 
Treatment of guinea pig hepatocyte cultures with MEHP resulted in an 
increase in triglyceride concentrations in the hepatocytes. In rat and rabbit 
hepatocyte cultures, triglyceride concentrations were much less altered by 
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MEHP. In monkey hepatocytes a decrease in hepatic triglyceride concentration 
was found after treatment wi th MEHP. These effects are in agreement w i t h 
in vivo effects observed before. 
After treatment of primary hepatocyte cultures with MEHP, high 
concentrations of ω- and (ω-1 )-hydroxylated metabolites of MEHP were found 
in media from rat, rabbit and guinea pig cultures. The formation of these 
metabolites did not decline in t ime. During treatment the metabolite profile in 
media from rat hepatocytes moved towards ω-hydroxy metabolites of MEHP. 
In media from monkey hepatocytes the lowest concentrations of hydroxylated 
metabolites were determined. No major species differences were found in the 
potency to form oxidized MEHP metabolites, and thus no unique metabolite 
differences were found, which could explain the species differences in 
sensitivity for peroxisome proliferation. 
Introduction 
The current interest in peroxisome proliferation by xenobiotics, is the result 
of the finding that chronic exposure of rats and mice to peroxisome 
proliferators, eventually results in the development of hepatic tumours. The 
basic mechanism(s) by which peroxisome proliferators induce tumours in rats 
and mice is unknown. Tumour formation might be due to promotion of 
preneoplastic cells to cancer and/or might be the result of an increase in 
number and volume of peroxisomes [1] . In this latter model it is proposed that 
hydrogen peroxide, produced by the increased peroxisomal fatty acid ß-
oxidation system, results in oxidative damage of the genome [2]. Peroxisome 
proliferation might be the result of a disturbed fatty acid homeostasis in liver 
cells, probably related to an increased formation of ω-hydroxy fatty acids by 
cytochrome P450 4A1 [3] . If indeed peroxisome proliferation is an 
intermediate step in tumour formation, it remains uncertain whether 
peroxisome proliferating compounds are a health hazard for humans, since 
humans are considered to be less sensitive for peroxisome proliferation than 
rats. 
Peroxisome proliferation has been demonstrated in most mammalian 
species. Rats and mice are considered t o be very sensitive, hamsters and 
possible rabbits are intermediate sensitive, while dogs, cats, and monkeys are 
weak reactors [4-11]. Mechanisms underlying these species differences in 
sensitivity for peroxisome proliferation, are not very well understood. Species 
differences in the presence of specific receptors [12] and species differences 
in the metabolism or pharmacokinetics of peroxisome proliferating compounds, 
have been proposed [13, 14]. 
Forthe Polyvinylchloride (PVC) plasticizerdi(2-ethylhexyl)phthalate(DEHP), 
formation of a specific metabolite (e.g. metabolite VI (see figure 1 ) is proposed 
to be essential for induction of peroxisome proliferation [ 1 4 ] . DEHP is a rela­
tively weak peroxisome proliferator, but since this compound is used in large 
quantities and since DEHP is also an important environmental pollutant [15] , 
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Figure 1 - The metabolism of MEHP MEHP can undergo ω- and (ω-D-hydroxylation 
reactions, with as (final) products metabolite IX, VI, V and I Numbering of the 
metabolites is according to Albro et al. [38]. 
it is believed that a large number of people are exposed to this compound. 
Primary cultures of rat, monkey, human, dog, hamster and guinea pig 
hepatocytes have been treated in vitro with peroxisome proliferating 
compounds [9, 11, 14-18]. Primary cultures of rabbit hepatocytes have not 
been tested, yet Several markers for the response have been determined 
including peroxisome morphometries, increases in the activity of peroxisomal 
enzymes, lauric acid ω-hydroxylation activity and levels of RNA for 
peroxisomal enzymes and P450 4A1. Other parameters associated with 
peroxisome proliferation, like hepatic lipid levels (triglyceride and cholesterol 
concentrations) [7], have not been determined after in vitro treatment of 
hepatocytes with peroxisome prohferators. These parameters are of interest 
since peroxisome prohferators alter the fatty acid homeostasis in liver cells, 
indicating that both the fatty acid catabolic reactions (ß-oxidation activities), 
as well as anabolic reactions (triglycerides synthesis) might be altered. 
Studies on species differences in peroxisome proliferation should include 
studies with human hepatocytes. However, practical considerations (i.e. the 
poor availability of human livers, technical difficulties in establishing good 
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monolayer cultures and the relatively large numbers of cells required for 
analysis of microsomal enzyme activity) prompted us to use monkey 
hepatocytes in our experiments. 
In the experiments described in this paper, we have compared the effects 
of metabolites of DEHP (see figure 1 ) in primary hepatocyte cultures of rat, 
rabbit, guinea pig and on Cynomolgus monkey hepatocytes. Parameters 
determined (peroxisomal palmitoyl-CoA oxidase activity, lauric acid 
hydroxylation activities, RNA levels for acyl-CoA oxidase and P450 4 A 1 , 
triglycerides- and cholesterol concentrations) were studied in relation to the 
potency to form metabolites. 
Materials and methods 
Chemicals 
Collagenase В, cholesterol and triglycerides test kits were obtained from 
Boehringer Mannheim GmbH, Germany. Palmitoyl-CoA, hydrocortisone-21-
hemisuccinate, insulin, gentamycin sulfate, BSA, aminotriazole, NADPH, lauric 
acid were obtained from Sigma Chemical Co. (St Louis, MO, USA). 2,7-
Dichlorofluorescin diacetate was purchased from Eastman Kodak Co. 
(Rochester, NY, U.S.A.). 18-Crown-6-ether and 4-(bromo-methyl)-6,7-
dimethoxycoumarin were from Aldrich Chemical Co. (Milwaukee, Wl, U.S.A.). 
Triethyloxonium tetrafluoroborate was from Lancaster Synthesis Ltd 
(Morecamb, UK). Newborn Calf Serum, William's E powder and L-glutamine 
were obtained from Flow Laboratories. 
A cDNA probe for rat cytochrome P450 4A1 was provided by Dr. G.G. 
Gibson, University of Surrey, UK. A cDNA probe for rat acyl-CoA oxidase was 
provided by Dr. Hashimoto, Shinshu University School of Medicine, Japan. 
MEHP ( 9 9 % pure) was synthesized as described elsewhere [19]. Mono-
hexylphthalate was synthesized according to the same procedure. Mono-(2-
ethyl-5-oxohexyl)phthalate (metabolite VI) (99 % pure) was synthesized by 
Drs. Nefkens and van Zeist (Department of Organic chemistry. University of 
Nijmegen). Mono-(5-carboxy-2-ethyl-pentyl)phthalate (metabolite V) (96 % 
pure) was a kind gift of Dr. Sjöberg (Department of Drugs, National Board of 
Health and Welfare, Uppsala. Sweden). The identity of all metabolites was 
confirmed wi th NMR and MS. 
Isolation of hepatocytes 
Male Wistar rats (Cpb:WU) (Rattus norvegicus) (200 g), Male Dunkin 
Hartley guinea pigs (Cavia porcellus) (350g) and male New Zealander rabbits 
(Oryctolagus cuniculus) (2500 g) were purchased from the Central Animal 
Laboratory, University of Nijmegen. 
Cynomolgus monkeys (Macaca fascicularis) were bred at the National 
Institute of Public Health and Environmental Protection (RIVM, Bilthoven, The 
Netherlands). Young monkeys (2 to 3 years old) served as donors for kidneys, 
used in the production of poliomyelitis vaccine at that institute. 
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Rats, rabbits and guinea pigs were anesthetized by i.p. injection of sodium 
pentobarbital. In Rabbits and guinea pigs, 2 % lidocaine was injected 
subcutaneously in the abdominal wall as well. Monkeys were premedicated 
i.m. wi th atropine and xylazine and anesthetized i.m. wi th ketamine. Monkey 
livers were perfused with ice-cold saline in situ and transported on ice to our 
laboratory within 60 minutes after hepatectomy. 
Isolation of hepatocytes was based on methods described by Berry and 
Friend [20] and by Seglen [21]. Monkey liver was perfused with 500 ml of a 
Ca2 +-free HEPES buffer containing 0.25 mM EGTA and 1000 ml of this buffer 
without EGTA, followed by a recirculating perfusion wi th a 0 . 0 5 % (w/v) 
collagenase containing HEPES buffer for 30 minutes. Guinea pig and rabbit 
liver were perfused with 500 ml Ca2 +-free HEPES buffer containing 0.25 m M 
EGTA and 500 ml buffer of this buffer without EGTA, followed by a 
recirculated perfusion with 0 . 0 5 % (w/v) collagenase for 10 minutes. Rat liver 
was perfused with 500 ml buffer of the Ca2 +-free buffer, followed by a 
recirculating perfusion with 0.05% (w/v) collagenase for 10 minutes. The 
perfusion rate was 50 mL/min and the temperature 37 °C. 
The liver was gently torn apart and cells were dispersed in a C a 2 + -
containing HEPES-TES buffer with 2 % bovine serum albumin. For all four 
species, hepatocytes were obtained by a similar purification procedure of 
repeated filtering, washing and centrifugation at 50g (rabbit, rat and guinea 
pig) and 100g (monkey). Cell yields and viability were assessed using the 
trypan blue exclusion test. Cell yield was for rabbits 1280 χ 1 0 e cells (80%), 
monkeys 1100 χ 10 e cells (89%), guinea pigs 700 χ 10 β cells (90%) and 
rats 4 0 0 χ 10 e cells (90%). Numbers in parenthesis are the viability of the 
cells. 
Cell culture and treatment 
Hepatocytes were plated at a density of 9 χ 10 e /10 mL medium in a 9 cm 
tissue culture dish (Nunc) in Williams' medium E supplemented with 5% (v/v) 
newborn calf serum, 2 mM glutamine, 1 //M insulin, 10 μΜ hydrocortison and 
gentamycin (50 mg/L). Cells were incubated in a humidified atmosphere in air 
(95%) and C 0 2 (5%) at 37 °C. During the first 4 h 4 mM Ca 2 + and 4 mM 
M g 2 + was added to the medium. After 4 h the medium was changed. 
After 24 h medium was replaced by medium containing various 
concentrations of mono(2-ethylhexyl)phthalate, metabolite V or metabolite VI 
dissolved in dimethylformamide (DMF) (final concentration DMF in medium 
was 0.1 % (v/v)). The culture media, containing the appropriate concentration 
of test compounds, were renewed every 24 h. 
The appearance of monolayers derived from all 4 species was very similar: 
cells attached and formed confluent monolayers within 24 hours after seeding. 
Cytotoxicity of the DEHP metabolites tested, was studied in parallel 
experiments. In all four species, there was no decrease observed in the 
activity of the mitochondrial enzyme succinate-dehydrogenasetowards 3-4,5-
dimethylthiazpol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (assayed 
according to Mossman [22] and Denizoit and Lang [23]), neither did the 
concentrations tested influence the lysosomal accumulation of neutral red 
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(assayed as described by Borenfreund and Puerner [24]). Ethoxyresorfurin O-
dealkylation (EROD) activities were determined after treatment for 72 h with 
50 μΜ B-naphthoflavone (BNF) according to Wortelboer et al. [25] . 
Cell harvesting and preparation of cell homogenates 
After 96 h cells were harvested by removing the medium, washing the 
monolayer twice wi th ice-cold saline and scraping with a rubber policeman in 
cold sucrose-EDTA-Tris buffer (0.25 M sucrose, 5 mM EDTA, 20 mM 
Tris/HCI, pH 7.4). Cells were centrifuged and the pellet was flash frozen in 
liquid nitrogen and stored at -80 °C. Cells were sonicated as described by 
Wortelboer et al. [24] using an MSE 100 Watt Ultrasonic Desintegrator. Part 
of the homogenate was flash frozen in liquid nitrogen and stored at -80 °C 
and it was used for determining lauric acid hydroxylation activities, triglyceride 
and cholesterol concentrations. Part of the homogenate was freeze/thawed 3 
times, followed by centrifugation at 9,000g for 10 min. Supernatants were 
quickly frozen in liquid nitrogen and stored at -80 °C until they were thawed 
for determining of palmitoyl-CoA oxidase activity. 
For the extraction of total RNA cells were harvested in 4 M guanidium 
isothiocyanate solution (pH 7), containing 0.1 M 2-mercaptoethanol, 0.01 M 
TRIS (pH 7.4), and 0 . 5 % N-lauroyl sarcosine. Total RNA was extracted 
according to the method of Cathala et al. [26]. Typical extractions yielded 80 
//g RNA per 90 mm dish. 
Biochemical determinations 
Palmitoyl-CoA oxidase was measured as described by Reubsaet et al. [27]. 
Lauric acid hydroxylation activities were determined as previously described 
[28J. Protein concentration was determined by the Coomassie-brilliant blue 
method [29] using crystalline bovine serum albumin as standard. Triglyceride 
and cholesterol concentrations were determined enzymatically using test kits 
from Boehringer Mannheim. 
Northern blotting 
Total RNA fractions were submitted to electrophoresis and transferred by 
capillary blotting to Hybond-N filters (Amersham International, UK). Filters 
were then hybridized to 3 2P randomly labelled full length cDNA probes. Filters 
were washed with high stringency (0.5xSSC, 55 °C). Filters were 
autoradiographed for 72 h. 
Analysis of metabolites in culture media 
After 48 (24-48) and 96 (72-96) h medium was collected and stored at 
-20 °C. A part of the medium was hydrolysed overnight wi th ß-
glucuronidase/arylsulfatase and the other part was left untreated. After the 
addition of the internal standard monohexylphthalate, samples were acidified 
and extracted wi th diethylether. After derivatization with triethyloxonium 
tetrafluoroborate samples were analyzed by GC-MS (Varían Saturn, GC-MS) 
as described elsewhere [30]. Identification of the metabolites was carried out 
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m/z 177) and retention times of pure standards. 
Quantification was carried out by reference to calibration curves 
constructed from (media) samples containing MEHP, metabolite IX, metabolite 
VI and metabolite V (see figure 1). Knowing that the slope of the calibration 
curves of all 4 metabolites was comparable, metabolite I was quantified using 
the calibration curve of metabolite V. 
Results 
Effects of metabolites of DEHP in rat hepatocytes 
The effect of treatment of rat hepatocytes with MEHP, metabolite VI and 
metabolite V on peroxisomal palmitoyl-CoA oxidase activity, is shown in figure 
2A MEHP and metabolite VI induced this activity dose-dependently. At the 
highest concentration tested (300 μΜ), this activity was 6-9-fold induced. 
MEHP and metabolite VI appeared to have the same potency to induce 
peroxisomal ß-oxidation. Metabolite V did not induce palmitoyl-CoA oxidase 
activity. 
Laurie acid ω-hydroxylation activity was dose-dependently induced by both 
MEHP and metabolite VI (figure 2B). At 300 μΜ this activity was 20-fold 
increased by MEHP, 55-fold by metabolite VI and 3-fold by metabolite V 
Laurie acid (w-l)-hydroxylation activity was 6-9 fold increased by both MEHP 
and metabolite VI (results not shown), but this activity is supposed to be not 
characteristic for P450 4A1 [31]. 
In figure 3 it is shown that after 96 hours in culture, the RNA levels for 
both cytochrome P450 4A1 and acyl-CoA oxidase are dose-relatedly induced 
by treatment with MEHP. 
The lowest concentration tested which significantly induced both 
palmitoyl-CoA oxidase activity and launc acid ω-hydroxylation activity, was 
for MEHP 60 μΜ and for metabolite VI 100 μΜ. From this experiment we 
concluded that metabolite VI and MEHP are equally potent in inducing 
peroxisome proliferation. In the further experiments we have limited the 
testing in hepatocytes of several species to only one metabolite, ι e. MEHP 
Effects of MEHP in hepatocytes of rabbits, guinea pig and monkey compared 
to rat 
In parallel experiments it was shown that primary cultures of rat, monkey 
and rabbit hepatocytes, did respond to the known P450 inducer ß-naphtofia-
vone (BNF). EROD activities from BNF treated hepatocytes were 8-44 fold 
increased in rats, 70-140 fold in rabbits and 30-60 fold in monkeys. No 
induction of the EROD activity by BNF was found in guinea pig hepatocytes. 
Only at the highest concentration MEHP tested (600 //m), a 1.8-fold 
induction of palmitoyl-CoA oxidase activity was found in primary cultures of 
rabbit, guinea pig and male monkey hepatocytes (figure 4a). No induction of 
launc acid ω-hydroxylation (figure 4b) or (ω-1 )-hydroxylation activities (results 
not shown) was found in these 3 species A considerable inter-individual 
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Figure 2 - Effect of MEHP, metabolite VI and metabolite V on palmitoyl-CoA oxidase 
activities (A) and lauric acid w-hydroxylation activities (B) in primary cultures of rat 
hepatocytes.
Hepatocytes were preincubated for 24 hr, followed by 72 hr treatment. Each 
metabolite was tested in 3-4 experiments, in each experiment hepatocytes of 
different rats were used. Mean values ±  SD of these 3-4 experiments are presented. 
* significantly different (p ^  0.05) from 0//M  (ANOVA and Dunnett s test).
variation was observed in the parameters studied. In hepatocytes o f 3 female 
monkeys a significant (1.9 fold) induction of palmitoyl-CoA oxidase activities, 
after treatm ent w ith  600 //M  MEHP, was determined. No increase in lauric 
acid w-hydroxylation activ ity was observed (results not shown).
W ith the P450 4A1 and acyl-CoA oxidase cDNA probes used in the rat 
studies, no signals could be detected after Northern blot analysis o f RNA sam­
ples o f hepatocytes o f rabbit, guinea pig or monkey treated in v itro  w ith  
MEHP.
A fter treatm ent of guinea pig hepatocytes w ith  MEHP, an increase in
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Figure 3 - Northern analysis of RNA isolated from rat hepatocytes treated in vitro with 
MEHP. RNA samples (20 fjg) were hybridized with probes for peroxisomal acyl-CoA 
oxidase and cytochrome P450 4A1 
lane 1: 24 h after hepatocyte isolation
lane 2-7: 96 h after hepatocyte isolation and after treatment for 72 h with 0 ,
10, 30, 60, 100 and 300 //M MEHP.
triglyceride level in the hepatocytes was observed (figure 5A), while in (male) 
monkey hepatocytes triglyceride level was decreased. In hepatocytes of 
rabbits, triglyceride levels were slightly decreased after treatm ent w ith  60 and 
100 pM  MEHP, but a small increase was found after treatm ent w ith  600 pM  
MEHP. In rat hepatocytes no significant alteration in triglyceride levels upon 
treatm ent w ith  MEHP was found. Cholesterol concentration in the liver cells 
o f rat, guinea pig and monkey, were not influenced after treatm ent w ith  
MEHP, while in hepatocytes o f rabbits, a small decrease in cholesterol 
concentration was found after treatment w ith  high concentrations o f MEHP 
(figure 5B).
Summarizing, the effects o f MEHP in rat hepatocytes are much stronger 
than in hepatocytes o f the other three species.
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Figure 4 - Effect of MEHP on palmitoyl-CoA oxidase activities (A) and on lauric acid 
ω-hydroxylation activities (B) in primary cultures of rat, rabbit, guinea pig and monkey 
hepatocytes. 
Hepatocytes were preincubated for 24 hr, followed by 72 hr of treatment. Each 
metabolite was tested in 3-5 experiments, in each experiment hepatocytes of 
different animals were used. Mean values ± SD of these 3-5 experiments are 
presented. 
* Significantly different (p<0.05) from ΟμΜ (ANOVA and Dunnett's test). 
Biotransformation of DEHP metabolites in primary cultures of rats rabbits, 
guinea pigs and monkeys 
Rats: media samples were collected after treatment of hepatocytes wi th 
1 0 0 / У М MEHP. In the 24-48 h samples at least 4 metabolites were identified. 
Due to the availability of reference compounds for the metabolites VI, IX and 
V, we could positively identify these metabolites in our samples. The unknown 
metabolite is probably metabolite I, since the mass spectrum of this metabolite 
had a characteristic fragment of m/z 143. Almost all metabolites and the 
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Figure 5 - Effect of MEHP on triglyceride concentration (A) and cholesterol 
concentration (B) in hepatocytes of rat, rabbit, guinea pig and monkey. All values are 
expressed as percentage of control values. Control triglyceride values are for rat 135 
nmol/mg protein; for guinea pig 72 nmol/mg protein; for rabbit 148 nmol/mg protein 
and for monkey 172 nmol/mg protein. Control cholesterol values are for rat 145 
nmol/mg protein; for guinea pig 82 nmol/mg protein; for rabbit 148 nmol/mg protein 
and for monkey 196 nmol/mg protein. 
Hepatocytes were preincubated for 24 hr, followed by 72 hr of treatment. Each 
metabolite was tested in 3-5 experiments, in each experiment hepatocytes of 
different animals were used. Means ± SD of these 3-5 experiments are presented. 
* statistically significant (p<0.05) from 0 μΜ (Kruskal-Wallis and Mann-Whitney 
test). 
parent compound were present in non-conjugated form. In the 72-96 h 
samples the same 4 metabolites were determined, but now metabolite V and 
metabolite I were the major metabolites formed (figure 6). 
In media of primary cultures of rat hepatocytes treated with metabolite V, 
2 0 % was metabolized to metabolite I. Neither metabolite V nor metabolite I 
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Figure 6 - Concentrations of MEHP and its metabolites in media from primary 
hepatocyte cultures of rat, guinea pig, rabbit and (male) monkey treated in vitro with 
"ΙΟΟμΜ MEHP. 
Results after 48 h (24-48И) and 96 h (72-96 h) in culture are shown. 
Hepatocytes were preincubated for 24 hr, followed by 72 hr of treatment. Each 
metabolite was tested in 3 experiments, in each experiment hepatocytes of different 
animals were used. Mean values ± SD of these 3-5 experiments are presented. 
Key: Щ = glucuronidated metabolites, В = free metabolites 
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were conjugated. After treatment with metabolite VI no other metabolites 
were detected. A small proportion of metabolite VI was conjugated (results 
not shown). 
Guinea pia, rabbit and monkev: in media of hepatocytes of these three 
species treated in vitro with MEHP, the same 4 metabolites were identified as 
with the rat hepatocytes. In media from guinea pig and rabbit hepatocytes the 
concentration of oxidized metabolites in 24-48 h and 72-96h periods was 
comparable to the findings in the rat (figure 6). In media of primary cultures 
of monkey hepatocytes, lower concentrations of the oxidized metabolites 
were detected compared to rabbit and guinea pig. Furthermore, the 
concentrations of these metabolites in media from monkey hepatocytes 
declined in time. In guinea pig, rabbit and monkey, a major part of the parent 
compound MEHP and a part of the metabolites VI and IX, was conjugated. 
This conjugation activity was not lost during culture. 
Summarizing, all species showed metabolic capacity towards MEHP with 
a low oxidizing activity in monkey and a low conjugating capacity in rat. 
Discussion 
A major question in the assessment of carcinogenicity of DEHP and other 
peroxisome proliferators, is what mechanisms underly species differences in 
sensitivity for peroxisome proliferation. In addition, to assess the risk of these 
compounds for man it is necessary to quantify these species differences. 
In rat hepatocytes peroxisomal palmitoyl-CoA oxidase activity is already 
significantly increased (2.9-fold) at concentrations of 60 μΜ MEHP. In rabbit, 
guinea pig and monkey hepatocytes, a significant induction of this activity 
(1.8 fold) is observed only after treatment with 600 μΜ MEHP. These results 
indicate that MEHP can induce peroxisome proliferation in monkey, guinea pig 
and rabbit, but that these latter species are less sensitive for peroxisome 
proliferation than rat. Using linear regression analysis, we have calculated at 
which MEHP concentration the palmitoyl-CoA oxidase activity is 50% 
increased in the four species tested (table 1). This value is at least 30-fold 
higher for rabbit, guinea pig and monkey, than for rat. 
Our results with primary cultures of monkey and guinea pig hepatocytes, 
are in agreement with observations that these species are less sensitive for 
peroxisome proliferation than rat and mouse after in vitro and in vivo 
treatment with peroxisome proliferating compounds [4-11, 18]. Gibson [8] 
considered rabbits and hamsters to be intermediate sensitive for peroxisome 
proliferation. This conclusion was made after in vivo treatment with the 
peroxisome proliferating compound ciprofibrate. Our results on in vitro 
treatment of rabbit hepatocytes with MEHP, indicate that rabbits are not very 
sensitive for peroxisome proliferation. 
After treatment of rat hepatocytes with MEHP, we have found a close 
association between induction of lauric acid ω-hydroxylation activity and 
peroxisomal palmitoyl-CoA oxidase activity, in accordance with earlier 
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Table 1 - Estimation of the concentration of the DEHP metabolites causing a 50% 
increase in enzyme activity after in vitro treatment of hepatocytes of different 
species. 
Rat 
Rabbit 
Guinea pig 
Monkey 
MEHP 
Metabolite VI 
Metabolite V 
MEHP 
MEHP 
MEHP 
Palmitoyl-CoA 
oxidase 
activity 
14.8μΜ 
12.1 μΜ 
262 μΜ 
440 μΜ 
485 μΜ 
408 μΜ 
Laurie acid 
ω-hydroxylation 
activity 
4.5 μΜ 
6.9 μΜ 
78.6 μΜ 
ND1 
ND1 
ND1 
1
 It was not possible to calculate these values since activities decreased with 
increasing MEHP concentration. 
published studies [3, 4, 19]. Using linear regression analysis, we have 
calculated that a 5 0 % increase in lauric acid hydroxylation activities in rat 
hepatocytes is found at lower MEHP concentrations than a 5 0 % increase in 
peroxisomal palmitoyl-CoA oxidase activities (table 1), again demonstrating 
that induction of lauric acid ω-hydroxylation activities is the more sensitive 
marker for peroxisome proliferation. The increase in activity of these enzymes 
is accompanied by increases in mRNA level for these enzymes. This is partly, 
if not entirely, due to an increase in the transcription of the respective genes 
[32, 3 3 ] . However, the observed increase in palmitoyl-CoA oxidase activities 
in guinea pig, monkey and rabbit hepatocytes after treatment wi th MEHP, is 
not accompanied by an increase in lauric acid (¿/-hydroxylation activity. Similar 
findings have been reported after in vivo treatment of marmoset monkeys wi th 
ciprofibrate [10]. The proposed mechanistic inter-relationship between 
induction of peroxisomal enzymes and induction of lauric acid ω-hydroxylation 
activities as proposed by Sharma et al. [3], might therefore not be valid in 
rabbits, guinea pigs and monkeys. 
When we studied the triglyceride concentration in the MEHP treated 
hepatocytes, we observed different trends in the species tested. In guinea pig 
hepatocytes, hepatic triglyceride levels were increased by the MEHP 
treatment. In rabbit these levels were much less altered, while in monkey a 
decrease in hepatic triglyceride levels was found. Watanabe et al. [7] reported 
that after in vivo treatment of guinea pigs with the peroxisome proliferator 
bezafibrate, an increase in hepatic triglyceride level was observed, in rhesus 
monkeys a decrease was found, while in rat and rabbit no alteration of liver 
triglyceride levels was observed. The effects observed in our in vitro studies 
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with rabbit, monkey and guinea pig, show striking similarities with those 
observed after in vivo exposure. Further studies on species differences in fatty 
acid metabolism are necessary to explain these results. Kocarek and Feller 
[34] found a slight increase in triglyceride biosynthesis in rat hepatocytes 
treated in vitro with three peroxisome proliferating compounds. 
Mitchell et al. [14] have proposed that metabolite VI is the active 
peroxisome proliferator of DEHP in rats. We doubt if this is true since our 
studies indicate that both MEHP and metabolite VI have the same potency to 
induce palmitoyl-CoA oxidase activities and launc acid ω-hydroxylation. 
In addition our biotransformation studies indicate that the concentration of 
metabolite VI formed from MEHP in rats is low according to the effects found 
Our metabolism studies indicate that in all species the pattern of oxidized 
metabolites does not differ much between the species. Metabolite VI is 
formed in all four species. In monkeys the formation of oxidized metabolites 
decreased in t ime, indicating a loss of cytochrome P450 activity, since the 
hydroxylation of MEHP is P450 dependent [35]). In guinea pig and rabbit the 
amounts and pattern of oxidized metabolites found between 24-48 h and 
between 72-96 h were comparable. In rats higher concentrations of metabolite 
V and metabolite I were formed between 72-96 h compared to 24-48 h. This 
indicates that ω-hydroxylation activity towards MEHP is induced after 48 h. 
Lhuguenot et al. [36] studied the metabolism of MEHP in vivo and in vitro in 
the rat and observed that after repeated administration the concentrations of 
a/-oxidation metabolites of MEHP were increased. It is possible that the ω-
hydroxylation of MEHP is mediated by P450 enzymes associated wi th the ω-
hydroxylation of fatty acids [35] Induction of these enzymes by MEHP results 
not only in an increased ω-hydroxylation of fatty acids, but might also result 
in an increased ω-hydroxylation of MEHP. 
Metabolite I is supposed to be formed by (peroxisomal) ß-oxidation of 
metabolite V, and Turnbull and Rodncks [37] have proposed that monitoring 
the formation of metabolite I might be useful for quantifying the target-dose. 
Since guinea pig and rabbit, although less sensitive for peroxisome 
proliferation, do form high concentrations of metabolite I, we think that 
formation of metabolite I is not per se an indicator of increased peroxisomal 
ß-oxidation activities 
In media of hepatocytes from rabbit, guinea pig and monkey, glucuronide 
conjugates of MEHP, metabolite VI and metabolite IX were found. Metabolites 
V and I were hardly conjugated. The rat did hardly form any conjugated 
products at all. This finding is in accordance with the observations that rats 
do not excrete conjugated metabolites of DEHP in urine [38]. A lower 
conjugating activity towards DEHP metabolites in the rat might mean an 
increased bioavailability of these metabolites in the hepatocytes However, we 
doubt whether there is a causal relationship between induction of peroxisome 
proliferation and conjugating activity, since mice are very sensitive for 
peroxisome proliferation and do form conjugated DEHP metabolites [38] . 
Our studies show that the observed species differences in peroxisome 
proliferation, are not the result of species differences in the formation of 
active metabolites We propose that species differences in peroxisome 
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proliferation might be due to differences in fatty acid metabolism, in particular 
species differences in the partitioning of fatty acids between ß-oxidation and 
estenfication. With the recent description of a Peroxisome Proliferator 
Activated Receptor (PPAR) as a transcription factor for peroxisomal ß-
oxidation genes {review: Green [12]), it is also possible that species 
differences in peroxisome proliferation might be caused by variation in 
expression of PPAR, or in the regulation of the genes that are under control 
of this receptor. To assess the toxicity of peroxisome proliferating compounds 
to humans, further studies on species differences in peroxisome proliferation 
should focus on these two aspects. 
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Chapter 7 
Determination of four metabolites of 
the plasticizer di(2-ethylhexyl)phthalate 
in human urine samples. 
H.A.A.M. Dirven, P.H.H. van den Broek and F.J. Jongeneelen. 
Department of Toxicology, University of Nijmegen, 
The Netherlands. 
Int Arch Occ Env Hea, in press 
Abstract 
A method for biological monitoring of exposure to the plasticizer di(2-
ethylhexyl)phthalate (DEHP) is described. In this method the four main 
metabolites of DEHP (i.e. mono(2-ethylhexyl)phthalate (MEHP), mono(5-
carboxy-2-ethyDpentylphthalate, mono(2-ethyl-5-oxohexyl)phthalate and 
mono(2-ethyl-5-hydroxyhexyl)phtha!ate), are determined in urine samples. 
The procedure includes enzymatic hydrolysis, ether extraction and derivati-
zation with triethyloxonium tetrafluoroborate, respectively. Analysis is 
performed by gas chromatography-electron impact mass spectrometry. The 
detection limit for all four metabolites is less than 25 μg/L· urine. The 
coefficient of variation based on duplicate determinations of urine samples 
of workers occupat ional^ exposed to DEHP, was 1 6 % for MEHP (mean 
concentration 0.157 mg/L) and 6 - 9 % for the other three metabolites 
(mean concentrations 0.130-0.175 mg/L). 
The method described here was used to study DEHP metabolism in man. 
Most persons excrete mono(2-ethyl-5-oxohexyl)phthalate and mono(2-
ethyl-5-hydroxyhexyl)phthalate as a (glucuronide) conjugate. Mono(5-
carboxy-2-ethyl)pentylphthalate is mainly excreted in free form, while for 
MEHP a large interindividual variation in conjugation status was observed. 
Of the four metabolites quantified, 5 2 % are products of a (ω-U-hy-
droxylation reaction of MEHP (i.e. mono(2-ethyl-5-oxohexyl)phthalate and 
mono(2-ethyl-5-hydroxyhexyl)phthalate), 2 2 % is the product of a ω-
hydroxylation reaction of MEHP (i.e mono(5-carboxy-2-ethyl)pentylphtha-
late), and 2 6 % is not oxidized further (i.e. MEHP). A good correlation is 
obtained when the amount of MEHP ω-hydroxylation products is compared 
with the amount of MEHP (ω-D-hydroxylation products in urine samples. 
When the internal dose of DEHP has to be established, we recommend 
to study the levels of all four metabolites of DEHP in urine samples. 
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Introduction 
Di(2-ethylhexyl)phthalate (DEHP) is a plasticizer commonly used in 
Polyvinylchloride (PVC) plastics. In 1982 a study by the National Toxicolo-
gy Program of the USA was published in which DEHP was shown to induce 
liver tumors in rats and mice (NTP, 1982). The International Agency on 
Research of Cancer has classified DEHP as a possible human carcinogen 
(group 2b) (IARC, 1987). Since DEHP is not genotoxic, mechanisms leading 
to carcinogenicity are not very well understood (for review: Conway et al., 
1989). 
Our understanding of the metabolism of DEHP is largely due to the work 
of Albro and co-workers (for review: Albro et al., 1982 and Albro, 1986). 
In most species, including man, DEHP is rapidly hydrolyzed to mono(2-
ethylhexyllphthalate (MEHP) and 2-ethyl-1-hexanol (see figure 1). In the 
liver, MEHP can be oxidized by cytochrome P450 dependent reactions 
(Albro et al., 1984). Between species there are large differences in the 
excretion pattern of urinary DEHP metabolites. Rats for example, excrete 
more of the further oxidized urinary metabolites than man (Albro et al., 
1982, Albro, 1986). Rats do hardly excrete (glucuronide) conjugated meta-
bolites, in contrast to monkeys and man (Albro et al., 1982). 
Schmid and Schlatter (1985) described that after oral dosing of 2 
volunteers wi th DEHP, 11-15% of the dose was excreted in the urine, 
mainly in the form of conjugated metabolites. The halflife was estimated to 
be 12h. Schmid and Schlatter (1985) described seven metabolites, and the 
most important were MEHP, mono-(2-ethyl-5-hydroxyhexyl)pthalate 
(metabolite IX), mono(2-ethyl-5-oxohexyl)phthalate (metabolite VI) and 
mono(5-carboxy-2-ethyl-pentyl)phthalate (metabolite V). Numbering of the 
metabolites is according to Albro (1986). 
Exposure to DEHP has been studied in patients receiving a hemodialysis 
treatment, a blood product transfusion, undergoing cardiopulmonary bypass 
surgery and infants receiving an exchange transfusion (Sjöberg et al., 
1985; Nässberger et al., 1987; Flamino er al., 1988; Rock et al.. 1988; 
Barry et al., 1989). Little is published on occupational exposure to DEHP. 
In order to study the uptake of DEHP in man, we have developed a 
biological monitoring method. In this paper we describe a GC-MS method 
based on the simultaneous determination of four metabolites of DEHP (i.e. 
MEHP, metabolite IX, VI and V) in urine of workers occupationally exposed 
to DEHP. 
Methods 
Chemicals 
MEHP ( > 9 9 % pure) was synthesized as described elsewhere (Dirven et 
al., 1992). The internal standard mono(pentyl)phthalate (MPP, > 9 9 % pure) 
was synthesized according to the same procedures using 1-pentanol in stead 
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Figure 1 - Biotransformation of DEHP. DEHP is hydrolyzed by nonspecific hydrola­
ses to MEHP. Hydroxylation by cytochrome P450 enzymes may occur at the ш-
or at the (ω-1 (-position. Further metabolism by alcohol dehydrogenase enzymes 
and aldehyde dehydrogenase enzymes yield keto-metabolites or dicarboxylic acids. 
Dicarboxylic acids can undergo a ß-oxidation reaction (for review see Albro, 
1986). 
of 2-ethyl-1-hexanol. 
Metabolite VI (99% pure) and metabolite IX ( 9 1 % pure) were synthesi-
zed by Drs. Nefkens and van Zeist (Department of Organic Chemistry, 
University of Nijmegen, The Netherlands). Metabolite V (96% pure) was a 
gift of Dr. Sjòberg (Department of Drugs, National Board of Health and 
Welfare, Uppsala, Sweden). The identity of all four metabolites was 
confirmed wi th NMR and MS. 
ß-Glucuronidase/aryl sulphatase was obtained from Boehnnger (Mann-
heim, Germany). Triethyloxonium tetrafluoroborate was bought in diethyl-
ether from Lancaster Synthesis ltd (Morecamb, UK). When stored as a salt 
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at -20 °C, no loss of ethylating activity was observed. A working solution 
was obtained after pouring off the diethylether and dissolving the salt in 
dichloromethane (final concentration 0.5 M). The solution was filtered 
using a glass fiber filter. This working solution could be stored at -20 °C 
for up to 1 month. 
All other chemicals were of the highest purity obtainable. 
Calibration samples 
The metabolites were dissolved in methanol. Pooled urine samples of 
non-exposed persons were spiked with MEHP, metabolite V, VI and IX, 
yielding concentrations of 0, 0.1, 0.25, 0.5 and 1 mg of each metabolite/L 
urine (final concentration of methanol in urine was less than 1 % (v/v). 
These calibration samples were aliquoted and stored at -20 °C for maximal 
5 months. 
Treatment of urine samples 
Enzymatic hydrolysis To an aliquot of urine (5 ml), 10 ml 0.1 M acetate 
buffer (pH 4.9) was added and the pH was adjusted to pH 4.85-4.9 with 1 
M HCl. This mixture was incubated in duplicate overnight (16 h) with 12.5 
μ\ ß-glucuronidase/aryl sulphatase at 37 °C in a rotary shaking bath (200 
rpm). 
Extraction. To all samples 100 μ\ of a 200 μΜ solution of monopentyl 
phthalate was added as an internal standard. The pH of the mixture was 
adjusted to 1 with 3 M HCl and 2 χ 20 ml of diethylether was added. 
Samples were shaken for 15 min at high speed and the ether layer was 
removed. The combined ether extracts were evaporated at 30 °C under a 
gentle stream of nitrogen. 
Derivatisation: The metabolites were ethylated using a triethyloxonium 
tetrafluoroborate solution. To the dried ether extracts 25 μ\ triethylamine 
was added followed by 0.5 ml of a 0.5 M triethyloxonium tetrafluoroborate 
solution in dichloromethane. The formation of hydrogen fluoride was used 
for monitoring the derivatization reaction. The same volume of triethyl­
oxonium tetrafluoroborate solution was added to all samples within a serie. 
Excess dichloromethane was evaporated at 40 °C under a gentle stream of 
nitrogen. To the dried extract 1 ml of water was added followed by 
extraction with 2 χ 3 ml n-hexane. The combined extracts were evaporated 
to dryness under nitrogen at 45°C. The extract was dissolved in 0.5 ml 
toluene. 
Analysis by GC-MS 
GC-MS analysis was performed on a Varían Saturn GC-MS system 
controlled by a Compaq 386-20 personal computer using software version 
A (Varían, Houten, The Netherlands). A 30 m DB-5 column (J & W Scienti-
fic Folsom, California, USA) was used with 0.32 mm i.d. and 0.25 μπ\ film 
thickness. 
The 'on column injection' mode was used (SPI: Septum equipped tempe­
rature Programmable Injector). An aliquot (1 μ\) of toluene extracts was 
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injected in a deactivated high-performance liner (injection rate 5 //l/min). 
The initial injector temperature was 110 °C. After 1 minute the temperatu-
re rose to 280 °C (80 °C/min). After 4 minutes at 280 °C the temperature 
was lowered to the initial temperature by cooling wi th liquid carbon dioxi-
de. The initial oven temperature was 110 e C. After 1 min the temperature 
rose to 280 °C (10 °C/min) where it remained constant for 6 min. Helium 
was used as carrier gas (column f low was 0.8 ml/min). The interface 
temperature was 280 °C and electron impact was used as ionization mode. 
Data acquisition was performed in the auto ¡on mode in the mass range 
100-249, scan speed was 1 scan/second. 
Identification was carried out by the combination of full scan spectra 
(100-249 atomic mass units), selected ion fragments (m/z 149 and m/z 
177) and retention times of pure standards. 
Quantification was performed on mass fragment m/z 149 for the internal 
standard MPP, metabolite VI and metabolite V; mass fragment m/z 177 for 
MEHP and on mass fragments m/z 149 and m/z 177 for metabolite IX. 
Retention times were: 585 sec for MPP; 710 sec for MEHP; 810 sec for 
metabolite VI, 820 sec for metabolite IX and 910 sec for metabolite V. 
The metabolite/MPP areas ratio was calculated for each sample and 
quantified by comparing to a calibration curve, which was processed along 
wi th the series of samples. The mean of the duplicate determinations was 
used. 
The intercept of the calibration curves for metabolite VI , IX and V was 
not statistically significant different from zero. However, the intercept of 
the MEHP calibration curve was significant different from zero. This 
probably indicates that in the pooled urine sample used for preparation of 
the calibration curves a small background of MEHP was present. During 
quantification no correction was made for this background concentration. 
Determination of the creatinine concentration 
The urinary creatinine was determined with an automated analyzer 
technique based on the reaction of creatinine to alkaline picrate. 
Calculation of the coefficient of variation 
The coefficient of variation was calculated by using the formula: 
coefficient of variation = Z%D / η V2, in which π = the total number of 
duplicate observations. %D was calculated using the formula 
%D = ( | x, - x 2 | / 0.5(x, + x2) ) χ 1 0 0 % , in which x, and x 2 are the 
values of a duplicate observation. 
Results 
Chromatograms 
In figure 2A and 2B a mass chromatogram of a blank urine sample and a 
spiked urine sample is shown. A total ion current (or reconstructed ion 
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Figure 2 - CG-MS total ion chromatogram (TIC) and single-ion chromatograms at 
m/z 149 and m/z 177 of A) a blank urine sample and B) a spiked urine sample 
and C) an urine sample of a worker occupationally exposed to DEHP. 
peak 1 = MPP (internal standard), peak 2 = MEHP, peak 3 = metabolite VI, peak 
4 = metabolite IX and peak 5 = metabolite V 
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Figure 3 - Fragments of interest when DEHP metabolites are analyzed by mass 
spectrometry in the electron-impact mode. Mass fragment m/z 149 is formed from 
all ortho phthalic esters, mass fragment m/z 177 is formed when mono-esters of 
ortho-phthalic acid are ethylated. 
current) chromatogram is shown as well as single-ion chromatograms at 
m/z 149 and m/z 177. Mass fragment m/z 149 is characteristic for ortho-
phthalate compounds (both di- as mono-esters), while mass fragment m/z 
177 is characteristic for ethylated mono-esters (see figure 3). 
The mass spectra of the metabolites are not very characteristic due to 
the lack of fragments of the ethylhexyl moiety with sufficient abundance. 
The main fragments found were m/z 149 and m/z 177. The spectra of 
metabolite V showed a characteristic fragment of m/z 1 7 1 \ in the spectra 
of metabolite IX a characteristic fragment of m/z 157 2 was found and mass 
spectra of metabolite VI showed a characteristic fragment of m/z 1 2 7 3 . 
In figure 2C a chromatogram of an urine sample of a worker exposed to 
DEHP is shown. Although the concentrations of MEHP and metabolites V, 
VI and IX were relatively high, no major other peaks are detected w i t h 
mass fragments m/z 149 or m/z 177, which means that the four metabo­
lites determined were the main DEHP-metabolites. 
When studying the metabolism of MEHP in primary hepatocyte cultures 
of rat, rabbit, guinea pig and monkey, we have identified metabolite I. The 
retention time of this metabolite is 790 sec. In chromatograms of urine 
samples of workers exposed to DEHP, minor peaks were detected wi th this 
retention t ime. 
1
 [.CH2-CH(C2H5)-CH2-CH2-CH2-COO-CH2CH3] + 
2[-CH2-CH(C2H5)-CH2-CH2-CHO(C2H5)-CH3] + 
3[-CH2-CH(C2H5)-CH2-CH2-CO-CH3] + 
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Table 1 - Quantitative distribution of free- and conjugated metabolites in 5 human 
urine samples. Values are expressed as nmol metabolite/mmol creatinine. 
Values in parenthesis is the percentage of the free metabolites in relation to the 
total amount of metabolite. 
MEHP VI IX V 
free con- free con- free con- free con-
jugated jugated jugated jugated 
worker 1 
worker 2 
worker 3 
worker 4 
worker 5 
15 
(20%) 
27 
(38%0 
27 
(77%) 
4.2 
(100%) 
12 
(30%) 
61 
45 
8 
ND1 
32 
8 
(8%) 
8 
(9%) 
4 
(12%) 
3 
(20%) 
2 
(5%) 
96 
86 
29 
12 
35 
11 
(8%) 
ND1 
4 
(9%) 
2 
(12%) 
4 
(7%) 
123 
152 
42 
15 
52 
77 
(68%) 
95 
(60%) 
28 
(67%) 
6 
(55%) 
18 
(58%) 
36 
63 
14 
5 
13 
1
 = not detectable, concentration below the detection limit. 
Conjugated metabolites 
In urine samples of 5 men occupationally exposed to DEHP, we have 
determined the concentrations of MEHP and the metabolites V, VI and IX, 
wi th and without enzymatic hydrolysis. The results are presented in table 
1. Metabolites IX and VI were almost completely conjugated in all 5 
persons, while metabolite V was for 32-45% present in conjugated form. 
For MEHP a large interindividual variation was found. In urine samples of 
worker 3 and 4, MEHP was for 77-100% present in free form, while in the 
urine samples of 3 other men, only 20-38% of the MEHP was not conjuga-
ted. 
Sensitivity and reproducibility of the analysis 
The detection limits (signal/noise > 3) were 25 //g/L urine for MEHP, 25 
//g/L urine for metabolite IX, 13 //g/L urine for metabolite VI and 16 ^g/L 
urine for metabolite V. 
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Figure 4 - The amount of metabolite VI + IX versus the amount of metabolite V 
in urine samples from 15 men occupational^ exposed to DEHP. Metabolite V is 
formed after ω-hydroxylation of MEHP, while metabolite VI and IX are both 
products of {ω-1 )-hydroxylations. 
y = 20 + 1.77X, r = 0.958, ρ < 0.001 
A pooled urine sample from workers exposed to DEHP was aliquoted 
and 5 aliquots were analyzed in the course of 3 months. The fol lowing 
values ( ± SD) were obtained from these 5 determinations: for MEHP 86 ± 
17 ¿/g/L (range 71-106 μα); for metabolite IX 127 ± 14 //g/L (range 109-
146 //g); for metabolite VI 70 ± 10 //g/L (range 52-76 //g) and for metab­
olite V 91 ± 8 //g/L urine (range 79-101 //g). The day-to-day reproducibility 
is in the range of 9 to 20 percent. 
69 Urine samples from workers exposed to DEHP were analyzed in 
duplicate. When the concentrations determined were above the detection 
limits a coefficient of variation based on duplicate measurements was 
calculated. This value is 1 6 % for MEHP (n = 55), mean concentration 0.157 
mg/L; 6 % for metabolite VI (n = 52), mean concentration 0.169 mg/L; 9 % 
for metabolite IX (n = 60), mean concentration 0.175 mg/L and 9 % for 
metabolite V (n = 60), mean concentration 0.130 mg/L. 
These data show that the reproducibility of the method at the //g/L 
range is acceptable. 
Interindividual variation in metabolism of DEHP 
In order to select one metabolite as marker for DEHP-exposure, we were 
interested whether there are any interindividual variations in the metabolism 
of DEHP. Variation can occur in the rate of ω-hydroxylation or (a»-D-
hydroxylation activity of MEHP (see figure 1). In figure 4, the amount of 
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the product of the ω-hydroxylation reaction (metabolite V) is compared 
with the amount of the product of the (ω-11-hydroxylation reaction (meta­
bolite VI + metabolite IX) in post-shift urine samples of 15 men. A high 
correlation (r = 0.95) was obtained and no substantial interindividual diffe­
rences in the concentrations of the products of ω- or Ы-D-hydroxylation 
were found. The absolute concentration of the metabolites VI + IX was 1.7 
times as high as the concentration of metabolite V, which indicates that in 
human metabolism the (ui-D-hydroxylation reaction is favoured over the ш-
hydroxylation reaction. 
Discussion 
The use of the described GC-MS method in this study allowed the 
detection of concentrations of the four DEHP metabolites as low as 13-25 
^g/L urine. Since the four DEHP metabolites were detected in urine samples 
of workers occupational exposed to DEHP (Dirven et al.; 1993, see accom­
panying paper), this method is sensitive enough for the determination of 
occupational and medical exposure to DEHP. 
The determination of the four metabolites of DEHP is specific for 
exposure to DEHP, in contrast to earlier studies in which the total phthalic 
acid concentration in urine samples was used to assess exposure to DEHP 
(Liss et al., 1985 and Nielsen et al., 1985). The method described here, is 
reproducible and not very time consuming. The use of triethyloxonium 
tetrafluoroborate as derivatization agent is an improvement for the deter­
mination of monoesters of phthalic acid. This very powerful ethylating 
agent can be stored for a longer period, and the reaction is very fast and 
can be monitored by measuring the pH of the reaction mixture. 
After exposure of man to DEHP by inhalation, MEHP, metabolite V, 
metabolite VI and metabolite IX, are the major metabolites found. Our 
results indicate that man excretes DEHP metabolites in conjugated form, 
which is a major contrast to the rat, which hardly excretes conjugated 
metabolites of DEHP (Albro et al., 1982). 
In table 2 the urinary metabolite profile as found in the 15 men in our 
study is compared with the profile described in 2 other studies (Albro et al., 
1982; Schmid and Schlatter, 1985). The differences in these profiles 
reflect probably large interindividual differences in metabolism and/or routes 
of administration. 
In selecting metabolites of interest for biological monitoring of DEHP 3 
questions have to be studied: 
1) do interindividal differences in the metabolism of DEHP exist?; 
2) are there any metabolites which formation is specific for a toxic effect?; 
3) are there any practical (analytical-chemical) arguments which favours the 
choice for a specific metabolite? 
ad 1) Our results indicate that there are some but no large interindividual 
differences in the formation of the four major metabolites of DEHP in man. 
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Table 2 - Quantitative distribution of metabolites of DEHP in urine of humans. 
metabolite 
MEHP 
VI 
IX 
V 
total 
this study 
26 2% 
18.2% 
33 8% 
21.8% 
100%' 
Schmid and 
Schlatter, 1985 
10.5% 
24 2% 
32.5% 
33.0% 
100 2%2 
Albro 
eta/., 
1982 
25.4% 
16.8% 
50.3% 
7.4% 
99.9% 3 
1
 = metabolites were determined in urine samples of 15 man after a 8 hr exposi­
tion to DEHP. Intake of DEHP was probably a combination of inhalation during 
work and ingestion (background). 
7
 = these 4 metabolites accounted for 9 1 % of total metabolites quantified 
Metabolites were determined in urine samples of 2 man after oral dosing with 30 
mg DEHP 
3
 " these 4 metabolites accounted for 71 9% of total metabolites quantified. 
Metabolites were determined in pooled urine samples of 2 leukemia patients after 
intravenous administration of DEHP 
The rate of formation of ω-hydroxy metabolites is linear with the rate of 
formation of (ω-1 (-hydroxy metabolites. 
ad 2) Studies about toxic effects linked to specific metabolites are 
limited. None of the four metabolites were mutagenic in the Ames test 
using several typhimunum strains and different metabolic activation 
systems (Dirven et al., 1991). Metabolites associated wi th a toxicological 
effect include metabolite I (see figure 1), since this metabolite is supposed 
to be formed in (peroxisomal or mitochondrial) ß-oxidation (Albro, 1986; 
Turnbull and Rodncks, 1985). It is suggested that the quantity of metabo-
lite I formed, might serve as an indicator of peroxisomal activity, or as a 
surrogate of the target dose (Turnbull and Rodncks, 1985). However, we 
have found that metabolite I is not a major metabolite in human metabolism 
of DEHP. Metabolite VI was mentioned as the proximate peroxisome proli-
ferator in rats (Elcombe and Mitchell, 1986). 
Another metabolite of interest is metabolite V. It has been hypothesized 
that the induction of fatty acid ω-hydroxylation activity by peroxisome 
proliferating compounds, is an early, and possible obligatory, step in the 
induction of peroxisome proliferation (Sharma et al., 1988; Dirven et al., 
1992). Since there is evidence that the ω-hydroxylation of both MEHP and 
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fatty acids is catalyzed by the same P450 enzymes (Albro et al., 1984), 
the formation of metabolite V might be indicative for induction of these 
fatty acid ω-hydroxylating enzymes. This view is supported by the findings 
that, In rats treated in vivo or in vitro with DEHP, the metabolism is shifted 
to metabolites formed by ω-hydroxylation reactions (Lhuguenot et al., 
1985). However, when tested in primary cultures of rat hepatocytes, no 
induction of peroxisome proliferation was found after treatment wi th 
metabolite V (Elcombe and Mitchell, 1986). 
ad 3) Quantification of metabolite V in urine samples is somewhat 
favoured, since this metabolite appears in the latter part of the chroma-
togram free of interfering compounds, resulting in a baseline separation and 
therefore in a low detection limit and a low coefficient of variation. 
On the basis of the arguments mentioned above, we recommend to 
study all four metabolites of DEHP when the internal dose to DEHP has to 
be established. 
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Abstract 
Little is known about occupational exposure to the plasticizer di(2-ethyl-
hexyl)phthalate (CAS number 117-81-7), a compound widely used in 
Polyvinylchloride plastics. We have studied the uptake of DEHP in workers 
by determining the concentration of four metabolites of DEHP in urine 
samples, i.e. mono(2-ethylhexyl)phthalate (MEHP), mono(5-carboxy-2-
ethyUpentylphthalate, mono(2-ethyl-5-oxohexyl)phthalate and mono(2-
ethyl-5-hydroxyhexyl)phthalate. In addition DEHP concentration in the air 
was determined by personal air sampling. Nine workers in a PVC boot 
factory exposed to maximal 1.2 mg/m3 DEHP showed an increase in urinary 
concentration of all four metabolites over the workshift. These results were 
found on the first day of the workweek as well as at the last day of the 
workweek. With the exception of MEHP the increase in concentration of 
the metabolites during a workday was statistically significant. Six workers 
from a PVC cable factory exposed to maximal 1.2 mg/m3 DEHP showed a 
1-4 fold increase in the concentration of the four metabolites over the 
workshift, but these increases were not statistically significant. 
These results indicate that measurement of DEHP metabolites in urine 
samples may have utility for monitoring the occupational exposure to 
DEHP. 
Introduction 
Di(2-ethylhexyl)phthalate (DEHP; CAS number 117-81-7) is a odourless 
oily liquid. The compound is used in large quantities to make PVC plastics 
more flexible. Some synonyms of DEHP are dioctylphthalate, bis(2-ethyl-
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hexyllphthalate, hexaplas DOP, bisoflex DOP and flexol DOP (Burg, 1988). 
In 1985 approximately 24000 tonnes plasticizer were used in the Nether-
lands and 4 9 % of this amount was DEHP. PVC plasticized with DEHP was 
mainly used in the production of wrapping materials, tubes, shoe soles and 
floor covering (de Groot, 1987). 
The toxicological effects of DEHP have been reviewed recently (Turn-
bull and Rodricks, 1985; Burg, 1988; Albro, 1986; Stott, 1988). The most 
pronounced toxic effects of DEHP are the hepatocarcinogenic properties of 
this chemical in rats and mice. The International Agency on Research of 
Cancer has classified DEHP as a possible human carcinogen (IARC, 1987). 
Since DEHP is not genotoxic, mechanisms leading to carcinogenicity are 
not very well understood. DEHP might have promotional activity on tumor 
formation and/or might act as an epigenetic carcinogen (for review: Con-
way et al., 1989). This latter activity is probably associated with a bioche-
mical disturbance in the liver called peroxisome proliferation (Rao and 
Reddy, 1987). Identification of the hazard of DEHP to man is complicated 
by the fact that man and primates are less sensitive for peroxisome 
proliferation than rats and mice (for review: Rodricks and Turnbull, 1987; 
Stott, 1988). Mechanisms behind these species differences in sensitivity 
for xenobiotic induced peroxisome proliferation are not known. H o w e v e r , 
in a recent workshop on the health risks by DEHP the participants con-
cluded that DEHP possibly induce peroxisome proliferation in man and 
therefore is possibly carcinogenic to man (Schulz, 1989). 
The American Conference of Governmental Industrial Hygienists has 
classified DEHP as a substance of low toxicity by all routes of exposure 
(ACGIH, 1986). Many countries have set a threshold exposure level for 
DEHP at the workplace at 5 mg/m3 (ILO, 1989). In establishing this thres-
hold exposure level no reference was made to carcinogenic effects of 
DEHP. 
Absorption of DEHP during occupational exposure is most likely to 
occur by inhalation since the dermal absorption of DEHP in rats is low 
(Elsisi et al., 1989). DEHP has a low vapor pressure at ambient tempera-
tures and a moderate vapor pressure at enhanced temperatures (0.04 mbar 
at 120 °C; 4 mbar at 200 °C; data obtained from product information on 
hexaplas DOP from Imperial Chemical Industries PLC, Cleveland, England). 
These data suggest that exposure to DEHP by inhalation can be expected 
at high process temperatures 
Little is known about occupational exposure to DEHP. In a recent study 
in 9 PVC processing plants DEHP concentrations in the air were deter-
mined ranging from 0.02 to 0.5 mg DEHP/m3 (Vainiotalo and Pfäffli, 1990). 
No increase in the number of chromosome abberations were found in 
10 workers exposed for 10-30 years to DEHP (Thiess and Fleig, 1978). In 
two studies the excretion of phthalic acid by workers in PVC industries was 
determined as marker for exposure (Liss et al . , 1986, Nielsen et al . , 1985). 
Determination of the phthalic acid concentration in urine samples is how-
ever not an agent-specific method for biological monitoring of DEHP. It still 
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Figure 1 - Structures of the metabolites of DEHP determined in this study. 
Numbering of the metabolites is according to Albro et al., 1986. 
information about the exposure of workers. We have recently developed a 
method for the determination of four metabolites of DEHP (figure 1) in urine 
samples (Dirven et al . , 1993; see accompanying paper). This report is 
intended to investigate the utility of measuring the concentrations of four 
metabolites of DEHP in urine samples as an index of occupational exposure 
to DEHP. 
Methods 
Chemicals 
DEHP (99% pure) and carbon disulfide were obtained from Merck, 
Darmstadt, Germany. Tricosane was obtained from Aldrich Chem. Co. 
Milwaukee, W l , USA. All other chemicals were of the highest purity 
obtainable. 
Field measurements 
Studies were performed in 2 plants: a PVC boot factory and a cable 
factory. Personal data of the workers involved are shown in table 1. 
Boot factory. In this factory hexaplas DOP was added to recycled PVC 
together wi th coloring materials, dibutylphthalate and other additives. 
Every week approximately 30 tonnes of DEHP were used. The mixture was 
warmed and mixed in a semi-open 'papenheimer' at 160 °C. After 30 
minutes the liquid PVC paste was transported to an extruder (working 
temperature 170 °C). Granules were cooled in water and stored for further 
processing. Production occurred in a batch wise manner. 
In each week three workers in a shift were monitored (working hours 
6.00 a.m.-2.00 p.m.). Measurements were performed for 3 consecutive 
weeks so nine workers were involved in this study. When the men started 
at monday 6.00 a.m. no (occupational) DEHP exposition had occurred in 
108 Chapter 8 
Table 1 - Personal data of the male workers involved in the biological monitoring 
study. 
Subject function age body wt smoking1 alcohol 
(a) (kg) consump-
tion2 
Boot factorv 
1 operator 
2 operator 
3 operator 
4 operator 
5 operator 
6 operator 
7 operator 
8 operator 
9 operator 
Cable factorv 
10 extruder 
11 granulating 
12 extruder 
13 granulating 
14 extruder 
15 extruder 
41 
59 
24 
55 
33 
31 
59 
30 
62 
28 
23 
57 
39 
? 
43 
100 
78 
66 
105 
110 
92 
84 
78 
96 
64 
104 
74 
83 
65 
82 
-
-
-
-
-
10-20 
-
<10 
-
10-20 
10-20 
-
10-20 
20 
" 
5 
4 
50 
10 
6 
14 
2 
8 
6 
12 
4 
0 
10 
15 
0 
1
 number of cigarettes/day. 
2
 number glasses (beer,wine,spint)/week. 
the last 48 h. Urine samples were collected at the first and the last day of 
the 5-day workweek, before work and after work. Workers 1-3 were 
studied in the first week, workers 4-6 were studied in the second week and 
workers 7-9 in the third week. At the first and last day of the workweek 
personal air sampling was employed on all three workers in a shift (two 
times 2 h for each worker on the first day and once 2 h for each worker on 
the last day). 
Cable factorv. In this factory a PVC paste was produced from DEHP, 
PVC granules and other additives in a closed, batchwise process (tempera-
ture 200 °C). Workers employed in the mixing and granulating processes 
stayed most of the time in a noise-closed cabin. In a semi-open process the 
produced PVC granules were used for the coating of electricity cables 
(process temperature 200 eC). The production and use of DEHP containing 
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PVC was alternated with non-DEHP containing polyethylene. When we 
started our studies 12500 kg DEHP/week had been used for at least 6 
weeks. 
Five men worked in each shift. When the men started at the first day 
in the workweek no (occupational) DEHP exposure had occurred in the last 
48 h. Six workers in two shifts (6.00 am-2.00 pm, 2.00 pm-10.00 pm) 
collected urine samples at the first and fourth day of the workweek, before 
work and after work. At the first day of the workweek personal air sam­
pling was employed on all workers in a shift (two times 2 h for each 
worker). 
Air sampling and analysis 
DEHP concentrations in the ambient air were determined by personal 
sampling as a 2h Time Weighted Average (TWA) concentration, according 
to method No. S40 of the U.S. National Institute for Occupational Safety 
and Health (NIOSH, 1977). Flow rate was 1 L/min and was checked before 
and after each air sample. The DEHP on the filters (mixed cellulose ester 
membrane filters, 37 mm, 0.8 //M, Schleicher and Schuell GmbH, Dassel, 
Germany) was extracted in carbon disulfide after the addition of the internal 
standard tricosane. 1 μ\ of the extract was injected on a Carlo Erba instru-
mentiazone, FTV series 4300 gas Chromatograph with a flame-ionization 
detector. Separation was achieved on a 25 m CP-SIL-5 column (Chrom-
pack, Middelburg, The Netherlands) with 0.22 mm i.d. and 0.20 μπη film 
thickness. Helium was used as carrier gas. The 'on column' mode was 
used. Injector and detector temperature was 300 °C. Initial oven tempera­
ture was 75 °C. After 1 min the temperature rose to 250 °C (15 °C/min) 
and was hold for 7 min. Retention time for tricosane was 12.05 min and 
for DEHP 13.7 min. Peak areas were compared with a calibration curve of 
DEHP in carbon disulfide. The detection limit was 1 //g/filter ( = 8.3 //g/m3). 
In control experiments, filters were spiked with 30 μg DEHP in carbon 
disulfide. The filters were dried at room temperature and used as described 
above to test the stripping from filters during sampling. No loss of DEHP 
was found. With the analysis of each series of filters, a filter spiked with 
DEHP and a blank filter were analysed to test for interferences. On the 
blank filters no DEHP was detected. The recovery of DEHP from spiked 
filters was > 9 7 % . 
Urine sampling and analysis 
All urine samples were stored in glass containers. Urine samples were 
frozen at -20 °C immediately after the collection. 
The concentration of four DEHP metabolites was determined with GC-
MS as described in detail in an accompanying paper (Dirven er al., 1993). 
Detection limits for the four metabolites were 25 ^g/L for MEHP, 25 //g/L 
for metabolite IX, 13 //g/L for metabolite VI and 16 //g/L for metabolite V, 
and the coefficient of variation ranged from 6-16 %. When concentrations 
of the metabolites were below the detection limit, a value of 2/3 of the 
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Figure 2 - Concentration of four metabolites of DEHP (A= MEHP, B= metabolite 
VI, C= Metabolite IX and D= metabolite V) in urine samples of 9 workers in a 
boot factory. 
Urinary creatinine was determined by an automated technique based on 
the reaction of creatinine to alkaline picrate. 
Results 
Urinary excretion of DEHP metabolites. 
Since the halflife for DEHP is approximately 12 h (Schmid and Schlat­
ter, 1985) we assumed that DEHP absorption during a 8 h workday could 
be demonstrated by comparing the concentration of the DEHP metabolites 
in urine samples collected at the end of a 8 h work period w i t h the concen­
tration of the DEHP metabolites in urine samples collected before work 
started. In addition, we expected that due to the short halflife of DEHP, 
urine samples collected after a period of more than 48 h without occupa­
tional exposure to DEHP could be considered as blank samples. 
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Table 2 - Median values of the concentrations of four DEHP metabolites in urine 
samples collected from 9 workers in a boot factory. Within parenthesis the range 
of the values is expressed. 
All values are expressed as nmol/mmol creatinine. 
MEHP 
Met VI 
Met IX 
Met V 
day 1 
before 
work 
35.6 
(8.6-52.6) 
10.5 
(1.5-17.4) 
30 2 
(12 4-41.2) 
24.4 
(10.5-44.6) 
after 
work 
49.5 
(24.1-67.9) 
p = 0.29' 
24.9 
(9.9-94.1) 
p = 0.011 
57 9 
(24.7-149.6) 
p = 0.021 
29.3 
(10.7-129.2) 
p = 0.051 
day 5 
before 
work 
32.7. 
(14.5-69.8) 
p = 0 292 
17.1 
(2.3-31.8) 
p = 0.072 
44.5 
(4.7-53.9) 
p = 0.212 
24.6 
(6.94-52.7) 
p = 0.082 
after 
work 
48.9 
(31.2-72 8) 
p = 0.201 
24.2 
(20.4-90.3) 
p = 0 .01 ' 
54.0 
(39.8-121.3) 
p = 0.05' 
37.9 
(25.0-141.4) 
p = 0.03' 
1
 = the metabolite concentration in the after work sample was compared with the 
metabolite concentration in the urine sample collected before work by means of 
the Wilcoxon test for paired samples, two tailed. 
2
 = the metabolite concentration in the urine samples collected at day 5 before 
work was compared with the metabolite concentration in the urine samples 
collected at day 1 before work by means of the Wilcoxon test for paired samples, 
two tailed. 
Boot factory. The concentrations of the DEHP metabolites determined 
in urine samples of 9 workers are represented in figure 2 and table 2. On 
day 1 as well as on day 5, the concentration of metabolite VI , IX and V 
was 1.2-2.3 fold increased in urine samples collected at the end of the 
workday compared to urine samples collected at the start of the workday. 
The increase was statistically significant. Median concentration of all four 
metabolites in the prework samples on day 1 and day 5 were equal. 
Cable factory. Urine samples from 6 different men in the cable factory 
were collected at day 1 and day 4 of the workweek at the start and at the 
end of the workday. In all urine samples collected prework at the start of 
the workweek all four DEHP metabolites were detected (table 3). Median 
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Table 3 - Median values of the concentrations of four DEHP metabolites in urine 
samples collected from 6 workers in a cable factory. Within parenthesis the range 
of the values is expressed. 
All values are expressed as nmol/mmol creatinine. 
MEHP 
Met VI 
Met IX 
Met V 
day 1 
before 
work 
15.1 
(4.9-25.5) 
4.0 
(3.0-5.3) 
11.3 
(7.3-16.9) 
5.2 
(3.1-10.8) 
after 
work 
17.9 
(3.6-61.4) 
p = 0.43' 
11.0 
(6.3-45.9) 
p=0.03 1 
17.8 
(7.3-108.6) 
p = 0.141 
11.0 
(4.3-64.9) 
p = 0.161 
day 4 
before 
work 
16.2 
(4.0-26.1) 
p = 0.562 
3.7 
(1.8-20.5) 
p = 0.782 
13.9 
(3.7-29.7) 
p = 0.682 
6.1 
(2.2-25.8) 
p = 0.31 2 
after 
work 
34.5 
(4.9-75.9) 
p = 0.15' 
16.6 
(2.2-37.5) 
p = 0.141 
25.9 
(17.9-75.5) 
p = 0.061 
15.1 
(7.1-37.9) 
p = 0.16' 
1
 = the metabolite concentration in the after work sample was compared with the 
metabolite concentration in the urine sample collected before work by means of 
the Wilcoxon test for paired samples, two tailed. 
2
 = the metabolite concentration in the urine samples collected at day 4 before 
work was compared with the metabolite concentration in the urine samples 
collected at day 1 before work by means of the Wilcoxon test for paired samples, 
two tailed. 
concentration of the metabolites in the urine samples collected after work 
was 1.2-4.5 fold increased compared to median values in the urine samples 
collected before work, but these increases were not statistically significant. 
The median concentration of the four metabolites in prework samples 
during the 2 days in the workweek was comparable. 
Personal air sampling 
In table 4 the mean concentrations of DEHP in the ambient air in the 2 
plants as determined by 2h TWA personal air samples, are shown. Within 
each plant exposure levels were determined by men working at the mixing 
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Table 4 - Mean concentrations of DEHP in the ambient air as determined by 
personal air sampling. All values are expressed in ¿/g/m3. 
η = the numbers of samples analysed and the values within parenthesis is the 
range. 
plant mixing extruder 
boot 
cable 
261 
η = 16 
(100-1214) 
180 
η = 8 
(9-809) 
120 
η = 11 
(48-278) 
239 
η = 13 
(10-1266) 
wide variation in exposure levels was found even during a day, probably 
due to the batch wise production processes. Between the plants the 
average DEHP concentrations in the ambient air were in the same range. 
The highest DEHP concentration found was 1.26 mg/m 3 . 
Discussion 
An uptake of DEHP during work was demonstrated in a PVC processing 
plant. For nine workers in a boot factory median values for three DEHP 
metabolites, i.e. metabolite VI, IX and V were higher in urine samples 
collected at the end of the workday compared to urine samples collected at 
the start of the workday. However, the increased postshift urinary DEHP 
metabolite concentrations of workers in a cable factory were not statistical­
ly significant. 
The concentration of the metabolites in urine samples of workers 
collected prework at the start of the workweek were higher than in a 
pooled urine sample of non-occupationally exposed persons used for 
constructing calibration curves (Dirven et al., 1993), although no occupati­
onal exposure to DEHP had occurred for at least 48 h (4 times the half life). 
This might indicate that the halflife of DEHP is much larger than 12h 
(Schmid and Schlatter, 1985). 
The concentration of the DEHP metabolites in the urine samples at the 
start of the workweek were higher for workers in the boot factory than for 
the workers in the cable factory. The difference in excretion of DEHP 
metabolites between the workers in the boot- and cable factory might be 
caused by the fact that in the boot factory the weekly amount of DEHP 
plasticized PVC produced is constant, while in the cable factory the 
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production is more variable since the production of PVC is interchanged 
with the production of polyethylene. Continuous exposure to DEHP might 
result in higher levels of DEHP (metabolites) in slow releasing compart­
ments, like adipose tissue. The concentration of the DEHP metabolites in 
urine samples collected prework at the start and at the end of the work­
week however, were in the same order of magnitude. This indicates that 
during a workweek no observable accumulation of DEHP did occur. 
The personal air sampling data of the 2 plants show that the occupatio­
nal exposure to DEHP is in the //g/m3-range. Our data are in the same order 
of magnitude as previous published exposure levels (Vainiotalo and Pfaffli, 
1990; Thiess and Fleig, 1978). No apparent relation was found between 
the concentration of DEHP in the air and the metabolite concentration in 
the urine. However, since we have only monitored workers for 2-4 h during 
a 8 h workperiod and the intra-day variation of DEHP concentrations was 
large, our dataset on the DEHP concentration in air is too limited to find 
such a correlation. In a forthcoming study it is necessary to monitor the air 
concentrations for 8 h. 
The lack of a relation between DEHP air levels and the levels of DEHP 
metabolites in urine samples might also be caused by the time schedule we 
have used for collection of urine samples. We have collected urine samples 
after a 8 h workperiod. It remains to be elucidated whether the concentrati­
ons of the metabolites are higher in urine samples collected at a later point 
in time. 
With our limited dataset we tried to estimate whether the increase in 
excretion of urinary DEHP metabolites during a workday was in the same 
order of magnitude as the DEHP uptake by inhalation. A worse-case 
approach was followed. For this calculation we used the data collected at 
the first day of the workweek of all 15 workers in both the boot- and the 
cable plant. The absorbed dose was calculated with equation 1 and the 
excreted dose was estimated with equation 2. 
Equation 1 : 
absorbed dose = C, * BV * t * r, in which: 
С, is the DEHP concentration in the air. In our calculations we have used 
the median value of all air samples collected on the first day of the work­
week in the boot- and cable factory ( = 137 //g/m3); 
BV is the breathing volume, and was assumed to be 28.6 L/min (moderate 
workload, based on literature data from Diem and Lenther, 1976); 
t is the exposure time, and was 8 h ( = 4 8 0 min); 
r is the retention of DEHP in the lungs, and was assumed to be 1 0 0 % . 
Equation 2: 
The excreted amount of DEHP metabolites in urine = ( C^^,, + С
тЛ
 ,„ + 
Cm« vi + C w V ) * daily creatinine excretion, in which: 
C.r»i,p, Cm r t ,x, C„m V ) and C ^ v is the median value of the mentioned 
metabolite after work minus the median value of the mentioned metabolite 
before work; 
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daily creatinine = the creatinine excretion in 24 h. According to the 
literature this excretion is 16 mmol/24 h (Diem and Lenther, 1976). 
According to equation 1 the maximum daily uptake of DEHP is 1.9 mg. 
Equation 2 shows that the total excretion of DEHP metabolites in urine is 
0.49 mg. These values are in the same order of magnitude which indicate 
the value of biological monitoring studies to assess exposure to DEHP. The 
remaining DEHP might be excreted via bile and faeces. In studies w i t h 
humans and wi th Cynomolgus monkeys (Schmid and Schlatter (1986); 
Astili, 1989) it was found that of an oral dose of DEHP 10-50 % of the 
dose was recovered in urine. According to this calculation the daily uptake 
of DEHP during a 8 h workday is estimated to be 1.9 mg ( = 27 //g/kg per 
day). Lacking a clear understanding of the mechanism of carcinogenicity of 
DEHP, human risk of cancer is based on rodent data. Application of various 
low dose extrapolation models lead to the prediction that the daily dose 
resulting in a lifetime risk on hepatocellular tumors of no more than 1 in 1 
million would be between 1.5 and 791 //g/kg per day, wi th the most likely 
figure being 116 дд/kg per day (Turnbull and Rodricks, 1985). In this risk 
assessment humans and rats/mice were assumed to be at the same risk at 
the same daily dose level of DEHP and it was assumed that DEHP's 
mechanism of carcinogenicity in rodents most likely involves its ability to 
induce peroxisome proliferation. There is however a substantial doubt if 
these assumptions are right. Our own studies have shown that primates are 
at least 30-fold less sensitive for peroxisome proliferation than rats (Dirven 
et al., unpublished results). 
We therefore conclude that occupational exposure to DEHP at concen­
trations as found in our study is not a major risk factor for developing 
hepatocellular tumors. 
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Chapter 9 
General discussion and summary 
Few compounds have been so thoroughly tested with respect to their 
potential toxicity as some of the peroxisome proliferators, but still the hazard 
of these compounds for man is hard to assess. As described in chapter 1 the 
carcinogenicity of DEHP and other peroxisome proliferating compounds might 
be due to a combination of initiation of DNA damage by oxidative stress and 
propagation of this damage by proliferative responses. Biological mechanisms 
leading to these responses, as well as the biological basis for possible species 
differences in these mechanisms are unknown. The incidence of primary liver 
tumors is low in the USA and West-Europe (Simonetti et al., 1991) so it is 
difficult to perform epidemiological studies aiming at identifying human risks 
of these compounds. A reliable risk assessment of DEHP and other peroxiso­
me proliferating compounds will be fascilitated by the identification of the 
biological mechanisms of action. 
9 . 1 - On t h e mechanism of peroxisome proliferation 
Peroxisome proliferating compounds can cause a variety of effects in 
rats/mice. In chapter 2 experiments are described in which effects of DEHP 
on the liver were compared with effects found in serum. The relationship 
between the observed changes in serum parameters with the effects found in 
the liver was not clear. Therefore we have focussed our further studies on 
effects of DEHP in the liver. 
A number of hepatic enzyme activities have been reported to be disturbed 
by peroxisome proliferating compounds. In 1988 Sharma er al. proposed a 
mechanistic inter-relationship between induction of peroxisomal palmitoyl-CoA 
oxidase activity and cytochrome P450 4A1 related lauric acid ω-hydroxylation 
activity. In order to determine lauric acid ω-hydroxylation activity, we 
developed a new assay based on the derivatization of lauric acid and its t w o 
metabolites wi th a fluorescent label. After derivatization metabolites were 
separated using reversed-phase HPLC (chapter 3). 
Applying this assay in a number of experiments (described in chapter 3,4, 
5 and 6) we have shown that the described method is sensitive and useful for 
determining lauric acid ω-hydroxylation activity in hepatic microsomal fractions 
and whole liver homogenates of different species. In the experiments 
described in Chapter 4 we have explored the proposed mechanistic inter-rela-
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tionship between cytochrome P450 4A1 induction and peroxisome prolifera­
tion. Rats were treated in vivo with different doses of DEHP and a dose-
dependent induction of both lauric acid ω-hydroxylation and peroxisomal 
palmitoyl-CoA oxidase activities was found. These results were confirmed 
after administration of metabolites of DEHP like MEHP, 2-ethylhexanol and 2-
ethylhexanoic acid and other inducers of peroxisomal ß-oxidation activity. 
In addition a number of other studies demonstrated: 
1. co-induction of peroxisomal ß-oxidation enzyme and microsomal lauric acid 
ω-hydroxylation activities in liver of rats (Lake et al., 1984; Bacher et al., 
1988; Makowska étal., 1990; Chinje étal., 1991; Bell étal., 1991a and 
1991b; Kozakuera/., 1991; Bell étal., 1992; Gibson, 1992), 
2. induction of both enzymes in the same part of rat liver (Bell et al., 1991a), 
3. appearance of mRNA encoding cytochrome P450 4A1 earlier than RNA 
encoding peroxisomal ß-oxidation enzymes after treatment of rats with 
peroxisome proliferating compounds (Milton era/., 1990; Bieriefa/., 1991: 
Bell et al., 1991a and 1991b), 
4. prevention of peroxisome proliferation by inhibition of lauric acid ω-hydroxy­
lation activity (Ortiz de Mantellano et al., 1992). 
These results and the results obtained in our own experiments provide 
further evidence for a close linkage between xenobiotic induction of 
cytochrome P450 4A1 and peroxisome proliferation in rats. Since a Peroxi­
some Proliferator Activated Receptor (PPAR) has been described to be 
involved in the transcription of acyl-CoA oxidase genes (Tugwood et al., 
1992), it is tempting to speculate about the role of PPAR in the induction of 
cytochrome P450 4A1. We suppose that PPAR is also involved in the 
transcription of cytochrome P450 4 genes. 
9.2 - Species differences in peroxisome proliferation 
Since a mechanistic inter-relationship between induction of cytochrome 
P450 4A1 and peroxisome proliferation may exist we wondered whether 
species differences in peroxisome proliferation are reflected by species 
differences in cytochrome P450 4A1 induction. As a first step in this 
approach we studied whether cytochrome P450 4A1 enzymes are present in 
human liver (Chapter 5). In microsomal liver fractions of 12 kidney transplant 
donors we detected pronounced lauric acid ω-hydroxylation and (ω-D-
hydroxylation activities. In contrast to rats, lauric acid ω-hydroxylation activity 
was two-fold higher than (ω-D-hydroxylation activity. Using an antibody 
raised against rat hepatic cytochrome P450 4A1, we were able to identify 
proteins in the microsomal fractions of human liver which were immunochemi-
cally related to rat cytochrome P450 4A1. However, no correlation was 
observed between the amount of protein present and lauric acid ω-hydroxyla­
tion activity. We concluded that cytochrome P450 4A proteins are present in 
human liver but that they have different physicochemical properties when 
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compared to rat cytochrome P450 4 A 1 . Final identification of human 
cytochrome P450 4A1 must await the sequencing of human cytochrome 
P450 4 genes. 
Species differences in induction of cytochrome P450 4A1 and peroxisomal 
palmitoyl-CoA oxidase activities have been studied after treatment of primary 
hepatocyte cultures of rat, rabbit, guinea pig and male and female monkey 
with a metabolite of DEHP, i.e. mono-(2-ethylhexyl)phthalate (MEHP) (Chapter 
6). In hepatocytes of rat a 5 0 % increase in peroxisomal palmitoyl-CoA oxidase 
activity was found at a MEHP concentration of 15 μΜ. In hepatocytes of 
rabbit, guinea pig and monkey a 5 0 % increase in palmitoyl-CoA oxidase 
activity was observed at a concentration of 410-480 μΜ MEHP. These results 
indicate that the latter three species are at least 30-fold less sensitive to 
induction of peroxisome proliferation than rats. The induction of peroxisomal 
palmitoyl-CoA oxidase activity in rats is accompanied by an induction of lauric 
acid ω-hydroxylation activity. This induction was not observed in guinea pig, 
rabbit and monkey. Similar findings have been reported by Makowska et al. 
(1991 ) after treatment of marmoset monkeys with a peroxisome proliferating 
compound. It seems that the mechanistic inter-relationship between induction 
of peroxisomal palmitoyl-CoA oxidase activity and microsomal lauric acid ω-
hydroxylation activity as found in rat hepatocytes is not observed in the other 
three species tested. 
Treatment of primary hepatocyte cultures with MEHP caused a decrease 
in hepatic triglyceride levels in monkey hepatocytes and an increase in hepatic 
triglyceride levels in hepatocytes of rat and guinea pig. Similar results have 
been found after in vivo treatment of these species with peroxisome 
proliferating compounds (Watanabe et al., 1989), which demonstrates the 
value of primary hepatocyte cultures in studying the effects of peroxisome 
proliferating compounds. The different trends in triglyceride levels observed 
among the species after treatment with peroxisome proliferating compounds, 
suggest that more basic research on species differences in hepatic fatty acid 
metabolism and the partitioning of fatty acids between ß-oxidation and 
esterification, is necessary to explain species differences in peroxisome 
proliferation. 
Species differences in peroxisome proliferation were not the result of 
species differences in the formation of specific metabolites, since the pattern 
of oxidized MEHP metabolites in media of hepatocytes from all species was 
comparable (chapter 6). 
9.3 - Human exposure to DEHP 
In view of the assessment and management of health risks of DEHP in 
humans it is necessary not only to study the toxicity of DEHP but also to 
make a reliable estimate of the internal exposure to DEHP. In Chapter 7 a 
method is described for biological monitoring of DEHP based on the determina-
tion of four metabolites of DEHP in urine samples. Included in the method is 
120 Chapter S 
an enzymatic hydrolysis, an ether extraction, a derivatization-reaction and 
analysis by GC-MS. Exposure of DEHP in 15 workers in DEHP using industries 
was studied by environmental- and biological monitoring (Chapter 8). By 
means of biological monitoring an uptake of DEHP during a 8 h workday was 
demonstrated. Total uptake of DEHP during a 8 h workday was estimated to 
be 1.9 mg/day (= 27 //g DEHP/kg.day). 
9.4 - Towards a risk-assessment of DEHP 
Only a few attempts were made to assess the human carcinogenic risk of 
DEHP, although there is a growing need for these assessments by regulatory 
authorities. It is beyond the scope of this thesis to provide a risk-assessment 
on DEHP, although the results of our studies can be useful for such an 
assessment. 
Current models designated as non-threshold models used in risk assess-
ment of genotoxic carcinogens assume that these compounds have mutagenic 
potency and that one or two mutations in a single cell are sufficient to initiate 
malignancy (Day and Brown, 1980). The multistage model is the model most 
widely used by regulatory agencies. The multistage model assumes additivity 
of background, which leads to low dose linearity. The Mantel-Bryan probit 
model assumes that the mechanism of the carcinogen is different from that 
of whatever causes the background incidence of tumors. Hence, risk may not 
be linear at low dose levels (Mantel et al., 1975). 
Turnbull and Rodricks (1985) have assessed possible carcinogenic risk of 
DEHP to humans, using four non-threshold models (i.e. multistage model using 
applied doses of DEHP, multistage model using surrogate data for target-site 
doses, Mantel-Bryan probit model using applied doses of DEHP and Mantel-
Bryan model using surrogate data for target-site doses). Results are reviewed 
in table 1. In these assessments, data from the NTP bioassay were used and 
humans and rats/mice were assumed to be at the same risk at the same daily 
dose level of DEHP. It was stated that the mechanism of carcinogenicity by 
DEHP most likely involves peroxisome proliferation. Application of the various 
extrapolation models lead to the prediction that the daily dose resulting in a 
lifetime risk of no more than 1 in 1 million would be between 1.5 and 791 
//g/kg per day (see table 1 ) . The authors concluded that the multistage model 
with the surrogate target site dose adjustment was the most appropriate 
model and that the most likely figure was 116 /yg/kg per day. Surrogate 
target-site doses were calculated from the production of metabolite I (see 
chapter 7) since the authors assumed that production of this metabolite is an 
indicator for peroxisomal activity. Since our studies demonstrate that rabbits 
and hamsters, i.e. species not very sensitive for peroxisome proliferation do 
produce this metabolite at the same rate as rats (chapter 6), we assume that 
this concept needs reconsideration. 
For genotoxic compounds, the presumption is made that there is no 
threshold-effect. For non-genotoxic chemicals it seems likely that a no-effect 
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Table 1 - Estimates of safe levels of exposure to DEHP 
(from: Turnbull and Rodricks, 1985) 
Virtually safe dose (risk < 10 e) 
(¿/g/kg per day) 
Extrapolation model 
Multistage with 
applied dose 
Multistage with 
surrogate dose 
Mantel-Bryan with 
applied dose 
Mantel-Bryan with 
surrogate dose 
Maximum 
likelihood estimate 
2.2 
116 
Lower 95th 
percentile estimate 
1.5 
86.3 
11.9 
791 
threshold does exist. The threshold model (application of a safety or uncertain-
ty factor to a no-observed-effect level (NOEL)) is normally used to predict safe 
levels of exposure for noncarcinogeniceffects (National Academy of Sciences, 
1977). Generally, this method has also been accepted to predict exposure 
levels for non-genotoxic carcinogens. Turnbull and Rodricks (1985) have also 
assessed possible carcinogenic risks of DEHP to humans applying a threshold 
model. In the case of DEHP such a threshold might be considered as the 
concentration of DEHP at which no induction of peroxisome proliferation is 
found. Turnbull and Rodricks (1985) identified a NOEL in rats for increases in 
peroxisomal ß-oxidation activity of 70-106 mg/kg per day. These levels are in 
the same range as we have found in our studies (chapter 4). In their 
assessment however they used a NOEL for all effects and applying a safety 
factor of 1000 they calculated a chronic acceptable daily intake of between 
70 to less than 3,5 //g/kg per day, with the most likely value being 11 /yg/kg 
per day. This value is lower than the estimated total uptake of DEHP during 
a 8 h workday ( = 27 //g DEHP/kg per day, chapter 8). 
A no-effect level for peroxisome proliferation is strongly species dependent 
as indicated by our data on species sensitivity for peroxisome proliferation 
(chapter 6). However, with the current knowledge that proliferative responses 
induced by peroxisome proliferating compounds might be important in the 
carcinogenic process as well (chapter 1.4.2), there is a urgent need for more 
information on these responses in primates/man. 
An adequate risk-assessment for DEHP or other peroxisome proliferating 
compounds seems hard to achieve. To our opinion the threshold model is at 
this moment the best model to predict safe exposure levels to DEHP. If 
122 Chapter 9 
peroxisome proliferation is indeed an intermediate step in the development of 
cancer by DEHP, the finding that primates are at least 30-fold less sensitive 
for peroxisome proliferation than rats, should be used in establishing a 
threshold. Present occupational exposure to DEHP seems to be low and it is 
unlikely that at this level of exposure a high risk for developing livertumors wil l 
be found. 
The best option for an adequate risk assessment of DEHP is a risk assess-
ment based on understanding the biological mechanisms leading to tumor 
formation and knowledge about the biological basis of species differences in 
these mechanisms. The discovery of PPAR might provide an unique insight in 
the mechanism leading to peroxisome proliferation. Green (1992a) proposed 
that PPAR might also mediate changes in key genes for growth and differenti-
ation like oncogenes and/or growth factors and their receptors. This might 
offer opportunities for receptor-mediated models for risk assessment (Green, 
1990; Cohen and Ellwein, 1991 ; Green, 1992a and 1992b). A threshold 
might be included in this model since it is likely that it is possible to determine 
concentrations below which no receptor activation will occur. A further 
implication of this model is that the receptor acts as a trigger for the biological 
effect of the chemical and therefore the abundance of the receptor in species 
and/or tissues is an important factor. 
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Samenvatting 
Mensen komen binnen en buiten hun werk in contact met chemische stof-
fen. Een aantal van deze stoffen kan kanker veroorzaken. Deze kankerverwek-
kende stoffen kunnen opgespoord worden door middel van testen, waarin 
bestudeerd wordt of chemicaliën het erfelijk materiaal van cellen beschadigen. 
Er zijn echter verbindingen die niet het DNA van cellen beschadigen, maar die 
toch kanker kunnen veroorzaken. In dit proefschrift is één zo'n stof bestu-
deerd, namelijk de weekmaker di-(2-ethylhexyl)ftalaat oftewel DEHP. Deze 
stof wordt aan Polyvinylchloride plastics toegevoegd om het plastic flexibel te 
maken. PVC plastics met daarin DEHP verwerkt worden o.a. gebruikt in 
regenpakken, vinyl vloerbedekking, laarzen, elektriciteitskabels, medische 
apparatuur en verpakkingsmaterialen voor voedsel. Het lijkt aannemelijk om te 
stellen dat iedereen elke dag wel in contact komt met een produkt waarin 
DEHP is verwerkt. 
Ratten en muizen die iedere dag met grote hoeveelheden DEHP worden 
behandeld krijgen leverkanker. Fabrikanten, werknemers en de overheid willen 
daarom graag weten of DEHP ook bij mensen leverkanker kan veroorzaken. 
Om deze vraag te kunnen beantwoorden is het noodzakelijk om eerst te 
bestuderen hoe DEHP kanker veroorzaakt. Op dit moment is dat nog niet 
bekend. Er zijn twee theorieën over hoe DEHP leverkanker kan veroorzaken. 
Theorie 1 gaat er van uit dat dit mogelijk iets te maken heeft met het vermo-
gen van DEHP om in levercellen een toename van het aantal peroxisomen te 
veroorzaken. Peroxisomen zijn net als mitochondriën en andere celonderdelen 
in iedere cel aanwezig. Met behulp van microscopen zijn peroxisomen zicht-
baar te maken in weefsel (zie chapter 1 , figure 1). Peroxisomen spelen een 
belangrijke rol bij het vetzuur metabolisme. Bij de afbraak van vetzuren in de 
peroxisomen ontstaat waterstofperoxyde, een stof die het DNA kan bescha-
digen. Doordat DEHP het aantal peroxisomen in levercellen doet toenemen, 
zou zoveel waterstofperoxyde binnen een levercel ontstaan dat het DNA 
beschadigd wordt. 
Theorie 2 verklaart het kankerverwekkend zijn van DEHP als een gevolg 
van een toename in het aantal celdelingen in de lever. Welk mechanisme deze 
toename veroorzaakt is op dit moment nog niet bekend. 
In hoofdstuk 1 wordt beschreven dat het aannemelijk lijkt dat juist een 
combinatie van de effecten zoals beschreven in de twee theorieën leidt tot het 
optreden van tumoren. 
Om de risico's van DEHP voor mensen te voorspellen, is het nodig om te 
weten of de toename in het aantal peroxisomen en het aantal celdelingen ook 
bij mensen wordt gevonden na blootstelling aan DEHP. In dit proefschrift is 
vooral bestudeerd hoe de toename van het aantal peroxisomen tot stand komt 
en of er soort verschillen bestaan in de gevoeligheid voor dit effect. Daarnaast 
is bestudeerd hoeveel DEHP mensen precies binnen krijgen als zij werken in 
fabrieken waar DEHP wordt gebruikt. 
Uit de resultaten van de uitgevoerde experimenten blijkt dat de effecten 
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van DEHP in de lever veel sterker en specifieker zijn dan de effecten van 
DEHP op enzymen in het bloed (hoofdstuk 2). Het is dus niet mogelijk om via 
het bloed van mensen te bestuderen o f er een toename van het aantal 
peroxisomen in de lever is.
De toename van het aantal peroxisomen w ordt waarschijnlijk veroorzaakt 
door een verstoring van de vetzuurhuishouding in levercellen. Deze verstoring 
zou mogelijk een gevolg kunnen zijn van een toename in de activ ite it van een 
enzym dat zorgt voor de hydroxylering van vetzuren. Dit enzym w ord t cyto- 
chroom P450 4A1 genoemd.
In hoofdstuk 3 w ordt een methode beschreven om de activ ite it van d it 
enzym te meten. Nieuw aan deze methode is dat gebruik w ord t gemaakt van 
een chemische reactie waarbij een fluorescerende groep aan de vetzuren 
w ord t gekoppeld, zodat de produkten gevoelig kunnen worden gemeten.
In hoofdstuk 4 worden experimenten beschreven waarbij de relatie tussen 
een toename in cytochroom  P450 4A1 en een toename in peroxisomen w ord t 
bestudeerd. Ratten zijn behandeld met een aantal metabolieten van DEHP en 
met een aantal verbindingen die mogelijk een peroxisoom proliferatie kunnen 
veroorzaken. Er b lijkt inderdaad een heel nauw verband te zijn tussen de mate 
waarin het cytochroom  P450 4A1 is toegenomen en de toename in het aantal 
peroxisomen.
In hoofdstuk 5 worden experimenten beschreven waarin bestudeerd w ord t 
of het cytochroom  P450 4A1 enzym ook in levers van mensen aanwezig is. 
Uit de resultaten b lijkt dat verwante enzymen inderdaad aanwezig zijn in 
levers van mensen, maar dat deze enzymen niet helemaal identiek zijn aan de 
cytochroom P450 4A  enzymen, zoals die gevonden worden in de lever van de 
rat.
Soortverschillen in gevoeligheid voor DEHP zijn onderzocht met behulp 
van geïsoleerde levercellen die blootgesteld werden aan afbraak produkten van 
DEHP. Al bij een concentratie van 15 //M  MEHP werd een toename in de 
activ ite it van peroxisomale enzymen gevonden. Bij levercellen van konijnen, 
cavia's en apen waren 30x hogere concentraties MEHP nodig om d it e ffect te 
bereiken. Na behandeling met MEHP was de activ ite it van het cytochroom  
P450 4A1 wèl toegenomen in de behandelde levercellen van de rat maar niet 
in levercellen van de drie andere soorten.
Als levercellen van apen een goed model zijn voor de levercellen van 
mensen, dan zou dit betekenen dat, in vergelijking met ratten ook bij mensen 
veel hogere doses DEHP nodig zijn om een toename van het aantal peroxiso­
men in de lever te krijgen. Als de toename in het aantal peroxisomen op een 
o f andere manier zorgt voor het ontstaan van tumoren, dan betekent d it dat 
de mens pas bij veel hogere doseringen DEHP levertumoren krijg t dan de rat. 
Definitieve uitspraken over de risico's van DEHP voor mensen moeten w ach­
ten to t het moment dat precies bekend is welke mechanismen leiden to t de 
toename in het aantal peroxisomen. Met de recente ontdekking van een 
receptor die betrokken is bij de toename van het aantal peroxisomen lijk t het 
aannemelijk dat binnenkort meer inzicht in deze mechanismen zal ontstaan. 
Om de risico's van DEHP voor mensen echt goed te begrijpen, is het echter
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ook noodzakelijk om de rol van de toename in celdelingen in het proces van 
tumorvorming te begrijpen. Nog onbekend is of de toename van celdelingen 
die door DEHP wordt veroorzaakt ook bij andere diersoorten dan ratten wordt 
gevonden. 
Voor het vaststellen van gezondheidsrisico's van DEHP is het ook belang-
rijk de blootstelling aan DEHP bij werknemers te onderzoeken. Een nieuwe 
methode is ontwikkeld om vier afbraakprodukten van DEHP in urinemonsters 
aan te tonen. Deze methode is beschreven in hoofdstuk 7. In urinemonsters 
van 15 werknemers, die tijdens het werk met DEHP in contact komen, konden 
alle vier de afbraak Produkten van DEHP aangetoond worden. In urinemon-
sters die aan het eind van de werkdag waren verzameld waren de hoeveel-
heden van de afbraakprodukten hoger, dan in urine monsters die aan het 
begin van de werkdag waren verzameld. Hiermee is aangetoond dat de 
werknemers lucht met daarin DEHP hebben ingeademd en dat dit DEHP is 
opgenomen in het lichaam (hoofdstuk 8). De opgenomen DEHP is echter erg 
laag, zeker als deze wordt vergeleken met de hoeveelheden DEHP die bij 
ratten en muizen levertumoren veroorzaakt. Als bovendien het optreden van 
levertumoren een gevolg is van peroxisoom proliferatie, dan moet rekening 
gehouden worden met het feit dat er zeer sterke soortverschillen zijn in 
gevoeligheid voor peroxisoom proliferatie. 
Op basis van deze argumenten kan geconcludeerd worden dat de beroeps-
matige blootstelling aan DEHP zo laag is dat de kans op het krijgen van 
leverkanker door DEHP waarschijnlijk verwaarloosbaar klein is. 
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Stellingen 
1. De bij ratten gevonden correlatie tussen het optreden van peroxisoom 
proliferatie en van inductie van cvtochroom P450 4A enzymen geldt 
niet voor primaten, konijnen en cavia's. 
Makowska et al., Arch Toxicol ЪЪ: 106-113, 1991; 
Dit proefschrift. 
2. De conclusie van Mitchell et al. dat mono(2-ethyl-5-oxohexyl)ftalaat de 
metaboliet van di(2-ethylhexyl)ftalaat is, die in hepatocyten van de rat 
in vitro peroxisoom proliferatie veroorzaakt, is onjuist. 
Mitchell et al., Toxicol Appi Pharmacol SO: 23-32, 1985; 
Dit proefschrift. 
3. Hoewel al een grote diversiteit van verbindingen bekend is, die een 
interactie aangaan met de Peroxisome Proliferator Activated Receptor 
(PPAR), is het op grond van de ligand specificiteit van dergelijke 
nucleaire hormoon receptoren te verwachten dat een nog onbekende 
intermediair de eigenlijke ligand vormt. 
Green et al., Biochem Pharmacol43: 393-401, 1992; 
Göttlicher er al., Proc Natl Acad Sci 89: 4653-4657, 1992. 
4. De stelling dat de mens, na blootstelling aan peroxisoom prolifererende 
verbindingen een kleinere kans heeft dan ratten/muizen op het krijgen 
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